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ABSTRACT
Adenosine 3',5'-cyclic monophosphate (cAMP) analogues have antiproliferative
effects on a range of cancer cells including breast, colon and lung. The most potent
analogue, described to date, is 8-chloro cAMP but its mechanism of inhibition is
poorly understood. The aim of this thesis was to investigate the mechanism of action
of cAMP analogues on human cancer cell lines, in particular the hormone-responsive
breast cancer cell line MCF-7.
Growth inhibitory effects of 8-chloro cAMP was confirmed on MCF-7 cells.
However, this effect was not present in serum-free conditions and the degree of
inhibition was dependent on the concentration of foetal calf serum in the medium.
This effect could also be demonstrated in the presence and absence of added oestradiol
suggesting that 8-chloro cAMP does not antagonise the oestradiol stimulation of MCF-
7 cells. Effects of 8-chloro cAMP were also tested on other cancer cell lines derived
from breast, ovary and colon. Inhibition of cellular proliferation was again
dependent on the addition of serum in the culture medium. Partial characterisation
and purification of serum was attempted in order to identify the component(s)
responsible for this serum-dependent 8-chloro cAMP inhibition. The component(s)
was heat labile and fractions separated by gel filtration chromatography containing
inhibitory activity were eluted before the major albumin peak. When medium
containing 8-chloro cAMP and serum was pre-incubated, antiproliferative activity
remained after removal of most of the serum components by ultrafiltration. In
serum-free conditions, phosphodiesterases conferred the ability to 8-chloro cAMP
to inhibit growth of MCF-7 cells; addition of a phosphodiesterase inhibitor appeared
to protect the cells from the antiproliferative effect in serum containing medium.
High pressure liquid chromatography of cAMP analogues incubated with serum or
with gel filtration fractions detected a peak that had identical UV spectrum and a
column retention time as an 8-chloro adenosine standard. The concentration of
adenosine analogue formed correlated with the concentration of serum in the medium
and the degree of growth inhibition. Purified 8-chloro adenosine was directly toxic
to MCF-7 cells cultured in the presence and absence of serum.
The data in this thesis suggest that 8-chloro cAMP (and 8-bromo cAMP) is
metabolised by serum borne phosphodiesterases and 5'-nucleotidases. The
antiproliferative effects of cAMP analogues in this culture system appear to be






cAMP cyclic adenosine 3':5* monophosphate
CAP catabolite activator protein
CAT chloramphenicol acetyltransferase
8 - CI 8-chloro
CPM counts per minute
CRE cAMP response element
CREB cAMP response element binding protein
CRP cAMP receptor protein
DBcAMP dibutyryl cAMP
DMBA 7,12-dimethyl-be nz(a) anthracene
DMB/I Dulbecco's Modified Eagles Medium
EDTA ethylenediaminetetraacetic acid
EGF epidermal growth factor
FCS foetal calf serum
G guanine
GAP GTPase activator protein
G-protein guanine nucleotide binding protein
3H tritium
HITS Hydrocortisone, Insulin, Transferrin and Selenium
(section 2.2.1)
HITS medium tissue culture medium containing HITS
HPLC high pressure liquid chromatography
IBMX isobutylmethylxanthine
IC50 50% inhibitory concentration
IF-s serum inhibitory factor(s)
igG immunoglobulin G
IPs inositol triphosphate
kinase A cAMP-dependent protein kinase
mRNA messenger RNA
p21 21 kDA protein product of the ras gene
PAGE polyacrylamide gel electrophoresis
PBS phosphate buffer saline
PDA piperazine diacrylamide
PDE cAMP-dependent phosphodiesterases
PDGF platelet derived growth factor
PRPP 5-phophoribosy1-1-pyrophosphate
Rl type I kinase A regulatory subunit
R11 type II kinase A regulatory subunit
SDS sodium dodecyl sulphate
T thymine
TEMED N,N,N',N'-tetraamethylethylenediamine
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INTRODUCTION
Introduction:
Cancer can currently be clinically approached by a number of
treatments, such as use of chemotherapeutic agents, radiation therapy,
and combination of both. These treatments typically reduce the growth
rate of the cancer, and in most part kill the cancer cells. A major
disadvatage to these treatments, however, is the fact that they are
harmful to normal cells, which limits the extent of treatment and may
cause incomplete elimination of the disease. On the other hand, therapy
targeted directly towards the cancer cell would improve the effectiveness
of the treatment and increase tolerance by the patient. For example, some
cancers, such as hormone-responsive breast cancer, can be treated with
chemotherapeutic drugs designed to antagonise the hormone
responsiveness of the cancer. Thus, a detailed understanding of the
factors involved in regulation of proliferation may help to identify
differences between normal cells and cancer cells (if such differences
exist) and enable design of more effective agents for chemotherapy.
cAMP, a mediator of hormone signals (Sutherland & Rail, 1975) has
been considered to play a role in cell growth and differentiation. The
potential use of cAMP as a chemotherapeutic drug has recently been
realised since the synthesis of specific cAMP analogues, which appear to
have a broad spectrum of growth inhibition on a variety of cancer cells
(Katsaros et al. 1987). The selectiveness of these agents for cancer cells
and their mechanism of growth inhibition is currently under investigation.
A discussion of factors involved in proliferation and the current
understanding of cAMP and cAMP analogues' growth regulatory mechanism
will be dealt with during the course of this introduction.
1
Factors Required For Culturing Cells:
The complexity of a multicellular organism makes it difficult to
study factors involved in cellular proliferation. However, established cell
lines, many of which are derived from cancer tissue, are capable of being
cultured in-vitro, thus enabling closer analysis of key components
required for growth. These cell lines are cultured in nutrient medium
containing essential amino acids, nucleic acids, and carbohydrates,
however, these ingredients alone do not maintain cellular proliferation,
but require specialised additives for continued growth. Many of these
specialised additives are supplied through the addition of serum, such as
horse, calf, or foetal calf to the nutrient medium.
The 3T3 mouse fibroblast line was one of the first established cell
lines in culture (Todaro & Green, 1963). When these cells are seeded at
low density, they have morphology resembling the primary cells used to
establish the cell line. In addition to having many of the primary cells'
growth characteristics, though enhanced, 3T3 cells frequently have
abnormal chromosome numbers. These "normal" cells grow in culture to
form a monolayer of cells and become growth arrested due to contact with
neighbouring cells.
The concept that multiple factors are required to be added to the
medium for optimum growth came initially from the observation that 3T3
cells grow better in animal sera obtained from clotted blood (serum)
rather than plasma (Ross et al., 1974, Kohler & Lipton, 1974). It was found
that a factor released from platelets gave optimum -growth. This platelet
derived growth factor, when added alone to serum-free medium, is a poor
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Hormones And Growth Factors:
Factors that control cellular proliferation and cellular metabolism
can be grouped under two general headings: steroid-like hormones and non¬
steroid factors.
Steroid hormones are hydrophobic molecules that can directly cross
the plasma membrane into the cytosol, and a cellular response to the
hormone is dependent on the cell possessing the hormone's specific
receptor protein. Binding of the hormone to its receptor results in a
conformational change in receptor structure, thus exposing a DNA binding
domain, which allows the receptor to directly interact with specific DNA
sequences. Many of these receptors have been cloned, and DNA sequence
analysis has confirmed a strong homology between the different types of
receptors, especially in the hormone binding and DNA binding regions
(Reviewed by Gehring, 1987). There are, however, small sequence
differences between these homologous regions which are enough to confer
ligand specificity for each receptor and interaction with specific DNA
sequences (Green & Chambon, 1987; Klock et al., 1987). Binding of the
activated steroid receptor complex (ligand-receptor) to chromatin results
in transcriptional regulation of a variety of genes. For example, the
steroid hormone oestrodiol can induce expression of a large number of
genes, many of which are involved in DNA replication, including DNA
polymerase, thymidine kinase, and dihydrofolate reductase (Lippman,
1980).
3
Physiological concentrations of oestradiol (10-8 - 10-9 M) can
stimulate growth of some cancer cell lines, including the hormone-
responsive breast lines MCF-7 (Lippman et al., 1976), ZR-75-1 (Darbre et
at., 1983), and the ovarian carcinoma lines PE01 and PE04 (Langdon et al.,
1990). In contrast, retinoids can be growth inhibitory to these types of
cells (Ueda et al., 1980, Lacroix & Lippman, 1980). There is, however,
accumulating evidence to support the thesis that hormones are not
mitogens, but induce the expression of genes which code for products that
are mitogens. Secretion of these products by the cell can then directly
stimulate adjacent cells in a paracrine response or directly feed back on
the secreting cell in an autocrine response (Sporn & Torado, 1980). Many
of these growth stimulating factors have been found secreted from human
breast cancer cells after addition of oestradiol (Bates et al., 1986;
Bronzert et al., 1987; Dickson et al., 1986; Huff et al., 1986).
These non-steroid factors, such as those secreted from oestradiol
stimulated cells, are small hydrophillic polypeptides with molecular
weights ranging from 1 to 40 kDa. Unlike hormone receptors, these
proteins are unable to permeate the plasma membrane directly, but bind to
specific receptor proteins situated within the plasma membrane with the
ligand binding site exposed on the extracellular side. These receptors are
anchored in the membrane and, therefore, require an alternative system to




Growth inducing factors regulate cellular metabolism through a
variety of transmembrane signalling mechanisms, which involve a series
of protein-protein interactions at the site of the plasma membrane. These
protein interactions result in the generation of a second messenger
product which is mobile in the cytosol.
Cyclic adenosine monophosphate (cAMP) is the best characterised
second messenger to date (Reviewed by Gilman, 1987). Ligand (e.g.,
acetylcholine, adrenaline) binding to specific receptors produces an
activated receptor complex which then interacts with membrane bound
small^ guanine nucleotide binding proteins (G-protein). This interaction
results in the exchange of GDP for GTP bound to the G-protein, thus
activating the protein. However, this activation is very short lived due to
the intrinsic GTPase activity of the protein. Activated G-protein can
interact with the effector protein, adenylyl cyclase, also located on the
membrane, which catalyses the conversion of ATP to cAMP. cAMP
continues to be generated as long as activated receptor remains coupled to
adenylyl cyclase via its G-protein. The elevation in cAMP concentration in
the cytoplasm is transient due to cAMP-dependent phosphodiesterases,
which convert cyclic AMP into inactive AMP. cAMP is the mobile second
messenger which can bind to the regulatory subunits of cAMP-dependent
protein kinases resulting in enzyme activation. These activated kinases
phosphorylate specific proteins, which can lead to functional changes such
as alteration in enzyme activity.
The above explanation of a G-protein describes the Gs protein
(stimulatory), however, the Gi protein (inhibitory) when activated (e.g.,
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ligand bound to muscarinic-type II acetylcholine receptor) inhibits the
activity of adenylyl cyclase (Matesic et al., 1991). Other G-proteins have
been implicated in the regulation of K+ channels, Ca2+ channels (Yantani et
al., 1990), and phospholipase C (Smrcka et al. 1991) and many have still to
have receptor and effector identified.
Another well characterised intracellular signalling pathway is the
hydrolysis of phosphatidylinositol 4,5-bisphosphate (Berridge & Irvine,
1984; MacPhee et al., 1984; Davis & Czech, 1985). Activated receptor (e.g.,
bombesin bound to its receptor) couples to the Gq protein, which then
activates the membrane bound enzyme phospholipase C (PLC) (Smrcka et
al., 1991). PLC hydrolyzes the membrane component phosphatidylinositol
4,5-bisphosphate, which generates two products inositol (1,4,5)
triphosphate (IP3) and diacylglycerol (DAG). IP3 is solubile in the
cytoplasm and is involved in increasing intracellular free Ca2+ ions. DAG
transiently activates the calcium-dependent, lipid-dependent protein
kinase C. Like cAMP, IP3 and DAG are short lived messengers, since they
are rapidly hydrolyzed by enzymes to inactive products. A similar system
has also been suggested for the hydrolysis of phosphatidylcholine
(Besterman et al., 1986; Roscoff et al., 1988).
Many of the growth factors, identified to date, appear to have
receptors with intrinsic tyrosine-specific protein kinase activity, for
example, epidermal growth factor (EGF) receptor, PDGF receptor, and
fibroblast growth factor (FGF) receptor (Sherr et al., 1985; Akiyama et al.,
1986). The tyrosine kinase is situated at the opposite end from the
extracellular receptor site within the cytoplasm. This is activated on
ligand binding to the receptor site and appears to autophosphorylate the
receptor. One of the consequences of this phosphorylation is a change in
conformation of the cytoplasmic domain of the receptor (Keating et at.,
1988). In this phosphorylated state, the receptor can physically interact
with cytoplasmic proteins that may be important in signal transduction
(Kazlauskas et at., 1990; Morrison et at., 1989). Phosphatidylinositol-3
kinase, for example, associates with the tyrosine phosphorylated PDGF
receptor resulting in the activation of this enzyme (Escobedo et at., 1991).
Many of the substrates for tyrosine phosphorylate receptors have still to
be identfied. Diagram 1 (page 9) schematically represents some of these
signal transduction pathways.
All components involved in signal transduction, the kinases that are
activated and kinases' substrates, are still poorly characterised.
Identification of the components of signal transduction and their function
is further complicated, since second messenger systems do not appear to
work in isolation of other pathways. Evidence has suggested that one
second messenger system can interact with the components of other
second messenger systems, consequently affecting the response of that
system (Huganir & Greengard, 1987; Hall et at., 1990). It has been shown,
for example, that phosphorylation of the nicotinic acetylcholine receptor
is catalyzed by at least three different protein kinases, cAMP-dependent
protein kinase, protein kinase C, and a tyrosine-specific protein kinase
(Huganir et at., 1984). Phosphorylation of this receptor by cAMP-dependent
protein kinase, however, increases the rate of desensitization which
reduces the degree of response to acetylcholine (Huganir et at. 1986).
Furthermore, Qureshi et at (1991) demonstrated that expression of a
primary response gene in 3T3 cells requires the interaction of tyrosine
kinase and kinase C. In addition to kinase effects, regulation of G-protein
7
coupling to effector has also been suggested. Yatani et at. (1990) suggest
from their data that the p21.GTP-GAP complex can interfere with the
coupling of the G-protein to K+ ion channels, thus preventing the channels
from opening. Many other signal transduction pathways are only now being
elucidated, such as the insulin receptor, prostaglandins, arachidonic acid,





Schematic representation of some signal transduction pathways.
R- receptor; G- G-protein; Gi- inhibitory G-protein;
Gs- stimulatory G-protein; AC- adenylate cyclase;
PLC- phospholipase C; PKC- protein kinase C.
9
Oncogenes:
Due to the complexity of signal transduction mechanisms, especially
the study of growth factor systems, virus induced tumour models have
been employed to identify the key components required for control of
proliferation. Identified viruses that can transform cells in culture into a
cancerous state include SV40, polyoma, and papilloma viruses (Bishop.
1985). Analysis of the viruses' genetic material has identified genes,
generally known as oncogenes, responsible for the transforming principle.
Many of these viral oncogenes appear to have strong DNA sequence
homology with host genes, so-called proto-oncogenes, which have the
potential to become oncogenes via mutation.
One of the first viral oncogenes recognised was ras oncogene, which
is responsible for the transforming principle of the Harvey and Kirsten
strains of rat sarcoma virus (Harvey, 1964; Kirsten & Mayer, 1967). Proto-
oncogenes of ras have also been widely identified in eukaryotic cells and
since the identification of transforming ras genes in human tumours
(Reviewed by Marshall, 1988; Barbacid, 1987), the study of ras has
become an area of intense research.
Ras genes code for 21 kDa membrane bound proteins (p21) that have
striking homology with G-proteins and possess intrinsic GTPase activity.
Many of the transforming p21 products appear to have a defective GTPase.
Hydrolysis of GTP by these transforming proteins is either impaired or non
existent, resulting in prolonged activation of p21 (McGrath et al., 1984;
Sweet et al., 1984; Willumsen et al., 1986; Lacal et al., 1986). The
striking similarities between p21 and G-proteins have led researchers to
postulate that p21 is involved in signal transduction. However, the
1 0
receptor that interacts with p21 and its downstream effector have still
to be elucidated. A possible effector for p21 is currently being
investigated since the discovery of GTPase Activating Protein (GAP)
(Trahey & McCormick, 1987).
Even though the role of p21 in signal transduction is not understood
completely, evidence has strongly implicated p21 in the role of
replication. As was shown by Stacey & Kung (1984), the mouse fibroblast
NIH/3T3 cells can be transformed by microinjecting viral p21. Using this
model, Mulcahy et al. (1985) demonstrated that microinjecting anti-p21
antibody during DNA replication (S phase) does not prevent NIH/3T3 cells
from completing replication. However, injection of anti-p21 antibody
before the start of S phase prevents the cell from initiating DNA
replication. Since the antibody can prevent initiation of S phase in the
presence of serum, the involvement of p21 in the initiation of DNA
replication is strongly implied. Moreover, the relevance of p21 in cellular
proliferation is corroborated by the observed incidence of ras gene
mutations in human tumours, including colorectal cancer (Bos et al.,
1987), acute myeloid leukaemia (Farr et al., 1988), and pancreatic
carcinoma (Almoguerra et al., 1988) of 25 - 50% or higher.
Like ras oncogenes, other oncogenes identified appear to have
products that are also involved in some aspect of signal transduction. One
such oncogene is v-s/'s which has strong homology with the (3-chain of the
mitogen PDGF and can transform cells that express the PDGF receptor
(Doolittle et al., 1983; Gazit et al., 1984). erb-B, another example, has
striking homology with the EGF receptor, but does not bind EGF and has a
constitutively active tyrosine-specific protein kinase (Downward et al.,
1984). In addition to erb-B, there are other oncogenes such as src, fms ,
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and Ick which code for products that also have tyrosine kinase activity
and are situated at the membrane (Jove & Hanafusa, 1987; Sherr et al.,
1985; Sefton, 1991). There are also oncogenes which code for products
that are located within the nucleus. Two such examples are myc and fos
whose products, when expressed in the presence of PDGF, have implicated
their importance in mitogenesis (Eisenman et al., 1985; Kelly et ai, 1983;
Cochran et al., 1984).
Controlling Proliferation Via Signal Transduction Pathways:
In light of the important role signal transduction plays in regulating
growth of cells, these pathways can offer a potential target for
controlling proliferation, especially with a view to regulating the growth
of cancer cells. So far, a number of approaches have already been
implemented based on the understanding of steroid hormones and growth
factors. Tamoxifen, for example, is an oestrogen antagonist and has proved
to be a valuable drug in the treatment of hormone-responsive cancers. It
prevents oestradiol from activating its receptor, thus inhibiting the
expression of mitogenic agents. Other approaches have been directed
towards using growth factor antagonists and the use of antiproliferative
agonists, such as the factor TGF-(3. Other methods being considered
involve regulating the expression level of oncogene products and
introducing second messengers involved in an antiproliferative effect.
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Cell Cycle:
It is important to understand that there are several stages to
cellular proliferation including DNA replication (S phase), mitosis and
cytokinesis (M phase) At each of these phases specific biological
components are required. Second messengers, produced in response to
extrinsic factors, induce a transient activation of key specific proteins,
many of which may only exist during a particular phase of the cell cycle.
Established cell lines have cell cycles with specific periods of time for
each phase, which can be manipulated by factors in the culture medium.
Alteration in the length of the cell cycle usually occurs in the phases
between mitosis (M phase) and DNA replication (S phase), known as G1
phase, and between S phase and M phase, known as G2 phase. This is
perhaps the simplest cell cycle known. Another type of cycle is one
associated with cells that are quiescent due to starvation of various
essential nutrients or due to confluence. Cells that lack essential
components, such as a growth factor or an essential amino acid, stop
cycling in the G1 phase in order to prevent premature arrest during
chromosomal replication in S phase (Prescott, 1976). This arrested state
is known as Go and is associated with a reduction in protein synthesis
(Austin & Clemens, 1981) and an increase in cAMP content (Boynton &
Whitfield, 1979). Addition of the missing component to starved cells can
bring about a transition from Go to G1 by reversing changes induced during
starvation, including initiating protein synthesis and reducing cAMP
content (Rochette-Egly et al., 1979; Whitfield et al., 1982). Some cells,
such as lymphocytes, hepatocytes, and pancreatic acinar cells, have a
different type of Go than the one described for quiescent cells starved of
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nutrients or confluent in culture. These particular cells retain protein
synthesis and have very little or no proliferation-related components
(Baserga, 1976). When stimulated, specific cell cycle genes are
transcribed, and some protein synthesis activity associated with the Go
phase are suppressed (Walker & Whitfield, 1981; Baserga, 1981). In order
to understand how second messenger systems can increase the rate of
proliferation, it would be necessary to identify the components involved
in these pathways during the different phases of the cell cycle. The
observation that quiescent cells have elevated cAMP levels and the fact
that chronic exposure of endogenous cAMP can cause growth inhibition led
to the hypothesis that cAMP was a negative regulator of growth. This
hypothesis was overwhelmingly supported due to numerous reports
detailing the inhibitory effects of cAMP derivatives and cAMP-elevating
agents (Reviewed by Ryan & Heidrick, 1974; Pastan et al., 1975). There is,
however, an alternative hypothesis that cAMP is a positive regulator of
proliferation (Reviewed by Boynton & Whitfield, 1983).
cAMP As A Positive Regulator:
In 1961, Selye et al. reported that exposure of the cAMP elevating
agent (3-adrenergic catecholamine to growth inactive acinar cells induced
a massive proliferative response. In addition, MacManus & Whitfield
(1969) reported that low concentrations of cAMP (10-8 - 10-6 M)
stimulated DNA synthesis of rat thymic lymphocytes. However, addition of
higher cAMP concentrations inhibited proliferation. cAMP and cAMP
elevating compounds have also been demonstrated as positive regulators
in cells from other tissues including liver, kidney, breast, and skin
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(Reviewed by Boynton & Whitfield, 1983).
Pancreatic acinar cells stimulated by the synthetic (3-adrenergic
catecholamine isoproterenol display two cAMP surges. The first peaks
after 10 to 15 minutes and the second 6 to 8 hours before the onset of
DNA synthesis (Durham et ai, 1974; Guidotti et at., 1972). Inhibition of
the second cAMP surge by propranolol 8 hours after isoproterenol addition
prevents initiation of DNA synthesis (i.e., entry into S phase), an effect
that can be overcome by the introduction of dibutyryl-cAMP (DBcAMP) and
theophylline (a phosphodiesterase inhibitor) (Tsang et al., 1980). These
cAMP surges have also been identified in other cells that respond to cAMP
as a positive regulator, and again the cAMP surge before S phase appears
to be important for initiation of DNA synthesis. However, if the fall of
cAMP in liver cells is prevented at the point of entering S phase, DNA
synthesis is inhibited (Boynton & Whitfield, 1979). These data suggest
that this second cAMP surge is required to initiate DNA synthesis and that
degradation of the cAMP is required for DNA synthesis to proceed. This
data could explain observations by other workers that high concentration
of cAMP or cAMP analogues present throughout the length of the cell cycle
can inhibit cellular proliferation.
cAMP As A Negative Regulator:
Negative regulation of cellular proliferation by cAMP, cAMP-
derivatives, and cAMP-elevating agents, though possibly not the normal
physiological role of cAMP in the cell cycle, offered a new approach to
controlling proliferation of cells, especially cancer cells. Ryan & Heidrick
(1968) observed that addition of cAMP (300 jj.M) to the culture medium of
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tumour cells, including HeLa, HEp-2, and F1 amnion lines, resulted in a
growth inhibition of up to 89% after an incubation period of four days.
This inhibition appeared to be dose-dependent and non-cytotoxic, since
cells resumed proliferating after removal of the second messenger.
Furthermore, addition of the cAMP metabolites, 5'-adenosine
monophosphate and adenosine produced no effect on cellular proliferation
in their culture system (Heidrick & Ryan, 1970). These observations of
inhibitory growth response were extended to in-vivo studies with tumour
models, such as Walker 256 and MTW9 mammary carcinoma, and 5123
hepatoma. cAMP analogues, such as N6, 02-dibutyryl-cAMP (DBcAMP) and 8-
Br cAMP, proved to be more efficacious than cAMP on inhibition of cellular
proliferation (Cho-Chung, 1974). The effectiveness of the analogues over
cAMP at equimolar concentrations might be explained by their increased
resistance to hydrolysis by phosphodiesterases (Moore et al., 1968).
Tumour Regression Associated Protein:
DBcAMP can inhibit growth of xenografts of the 7,12-dimethyl-
benz(a)anthracene (DMBA) induced hormone-responsive mammary
carcinoma (Cho-Chung & Gullino, 1974; Fluang & Cho-Chung, 1982) which is
also growth inhibited by oestrogen ablation (ovariectomy) (Huggins et al.,
1961). Cho-Chung & Redler (1977) attempted to understand the mechanism
of DBcAMP growth inhibition by studying nuclear protein phosphorylation
from isolated tumour nuclei, and identified a nuclear protein that was
phosphorylated in tumour treated with DBcAMP. The phosphorylation of
this protein disappeared on removal of DBcAMP or addition of oestradiol
(growth stimulatory) to the ovariectomized mice. Furthermore,
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cytoplasmic cAMP binding and protein kinase also appeared to translocate
to the nucleus in regressing tumour (treated with DBcAMP) (Cho-Chung,
1974; Cho-Chung & Clair, 1977). This accumulation of protein kinase in
the nuclei was previously reported from rat liver (Palmer et al., 1974;
Castagna et ai, 1975) and calf ovary tissue (Jungmann et al., 1974)
treated with cAMP, which led to the suggestion that a connection existed
between the mechanism of steroid growth stimulation and cAMP induced
growth inhibition. Cho-Chung & Redler (1977) concluded from these data




cAMP-dependent protein kinase (kinase A) is activated by the second
messenger cAMP which then leads to protein phosphorylation. The inactive
form of kinase A is a tetramer composed of two regulatory and two
catalytic subunits. Binding of cAMP to the regulatory subunits, of which
there are two binding sites per subunit, result in the dissociation of the
catalytic subunits from the regulatory dimer. The free catalytic subunits
are in an active state. Kinase A phosphorylate serine residues, and the
enzyme pyruvate kinase is a known substrate. The amino acid sequence of
pyruvate kinase was reported by Zetterqvist et al. (1976), and this
sequence was used to derive a synthetic peptide substrate for cAMP-
dependent protein kinase, Kemptide (Kemp et al., 1976). Other substrates
for kinase A include phosphorylase kinase and triacylglycerol lipase. The
ability of the catalytic subunit of kinase A to phosphorylate a serine
residue depends not only on the accessibility due to protein conformation,
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but also due to the surrounding amino acid sequence. The sequence
homology for potential serine phosphorylation appears to contain two
basic amino acids on the amino terminus end of the serine, one of which is
arginine, for example, Leu-Ara-Ara-Ala-Ser-Leu-Glv (pyruvate kinase,
Kemptide). The phosphorylation of enzymes by kinase A can result in the
modulation of their activity.
In most mammalian tissues there appear to be two types of kinase A
which were originally identified by their different retention
characteristics to ion-exchange chromatography columns (Krebs, 1972).
cAMP-dependent kinase activity eluted from the column with low salt was
termed type I and the second ,with a higher salt concentration termed,
type II. In addition, these different kinase A types also have different
binding affinities for cAMP, however, both types appear to have identical
catalytic activities (Beebe & Corbin, 1986; Weber et al., 1982).
Distinction between type I and type II resides in differences between the
regulatory subunits (R) which have approximate molecular weights of 49
kDa (Rl) and 55 kDa (Rll), respectively. The use of molecular biology has
identified four different mRNAs that code for regulatory subunits Rla (Lee
et al., 1983), Rlp (Clegg et al., 1988), Rlla (Scott et al., 1987) and Rllp
(Levy et al., 1988). Three isoforms of the catalytic (C) subunit have also
been identified: Ca (Uhler et al., 1986), Cp (Uhler et al., 1986) and Cy (Beebe
et al., 1990). Relative expression of each of these subunits varies in
different tissues, but preferential co-expression of either one of the
regulatory subunits with the catalytic subunits has not been found
(Showers & Maurer, 1986).
The function of the two types of protein kinase A have still to be
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fully explored. Kinase A exists in tissues as a mixture (Corbin et ai, 1975;
Hofmann et al., 1975), and the relative levels of each type could confer a
different response of the cell to cAMP. For example, high expression of
type I in a cell, which has a higher affinity for cAMP compared to type II,
could confer a greater kinase A activation for the same level of cAMP
compared with a cell containing higher expression of type II. This would
imply that cells expressing more type I than type II are more sensitive to
the presence of a ligand that produces cAMP as its second messenger.
Site-Selective cAMP Analogues:
Early studies involving the use of high concentrations of cAMP and
cAMP analogues were unable to determine the precise role of both types of
protein kinase A in cellular proliferation, since at millimolar
concentrations of cAMP or cAMP derivatives both regulatory subunits are
saturated. The advent of site-selective cAMP analogues enabled a more
detailed investigation into the role of each type of kinase in proliferation.
The two binding sites for cAMP on each regulatory subunit are denoted as
site 1 (or site B) and site 2 (or site A). Analogues that have the adenine
ring modified at position C-2 or C-8 selectively bind site 1, and C-6
modified analogues selectively bind site 2, as defined by binding studies
with purified subunit (Doskeland. 1978; Rannels & Corbin, 1980; see
diagram 2 for structure of cAMP; page 21). Competition studies of two
different analogues specific for the same binding site have shown that
they only compete for that one binding site on the regulatory subunit and
not the other. This competition is only minimally affected by addition of
an analogue that has specificity for the opposite binding site. Moreover, C-
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8-thio or halogen analogues preferentially bind to site 1 of type II rather
than type I protein kinase (Ogreid et al., 1985). These analogues are
therefore not only specific for a specific binding site but for a regulatory
subunit. Furthermore, the binding of an analogue to one site of a regulatory
subunit can cooperatively enhance the binding of ligand to the opposite
site. Therefore, addition of two site-selective analogues specific for
opposite sites of the regulatory subunit can synergistically activate the
protein kinase (Ogreid et al., 1985). However, potent activation of the
kinase is possible on addition of only one site-selective analogue
(Kerlavage & Taylor, 1982). This activation is presumably due to the
positive cooperativity that exists after a ligand has bound to one site,
thereby enhancing the binding of endogenous cAMP or the analogue for the
other site of the regulatory subunit. Alternatively, a single site-selective
analogue may lead to partial dissociation of the protein kinase A
holoenzyme; a stable complex of two bound ligands to protein kinase with
one dissociated catalytic subunit has been identified (Connelly et al.,
1986). The synthesis of site-directed cAMP analogues enables the
activation of specific kinase A types, thus facilitating investigation into




Diagram 2: Adenosine 3':5' cyclic monophosphate
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Antiproliferative Effect of Site-Selective Analogues:
Many of the early studies with DBcAMP required millimolar
concentrations of drug, and it was believed that many of the growth
inhibitory effects were due to toxicity. Furthermore, many of the
established cancer cell lines tested appeared to be resistant to DBcAMP.
In contrast, a range of site 1 and site 2 selective cAMP analogues
screened on a broad spectrum of established cancer cell lines, including
breast, colon, and lung, proved more effective than DBcAMP (Katsaros et
al., 1987). The most potent analogue tested was 8-chloro cAMP (8-CI
cAMP) (C-8 analogue) which had a 50% inhibitory concentration (IC50) on
cancer cells in the range of 1 - 25 pM after a four day exposure. The best
C-6 analogue was N6- benzyl with an IC50 of 15 - 25 pM. Moreover, the
addition of phosphodiesterase inhibitors, such as isobutylmethylxanthine
or theophylline, which when added alone had little effect on cellular
proliferation, did not enhance the inhibitory effect when added with these
cAMP analogues. This suggested that the toxic metabolites were not
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responsible for the antiproliferative effect by cAMP analogues (Tortora et
al., 1988; Cho-Chung et al., 1989). From these data it was concluded that
the concentrations required to produce growth inhibition were below
levels at which degradation of the analogue by phosphodiesterase could
take place. Furthermore, these analogues were considered to be non-
cytotoxic, since cells treated for three days with 8-CI cAMP (5 - 50 pM)
recovered and continued to proliferate after removal of the analogue.
Growth inhibition with 8-CI cAMP also appeared to be associated with a
decrease in the level of the ras oncogene product, p21, however, it was
not associated with a block in cell cycle progression (Katsaros et al.,
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1988; Tagliaferri et al., 1988). In contrast, addition of an 8-CI cAMP
metabolite, 8-CI adenosine, led to the conclusion that it was toxic to
cancer cells, since cancer cells exposed to equimolar concentrations of 8-
Cl adenosine for three days did not resume proliferating after removal of
the agent. Furthermore, a block in the cell cycle, between mitosis and DNA
replication, was evident and a change in expression of ras p21 was not
detected (Katsaros et ai, 1988; Tagliaferri et at., 1988). From these data,
the effects of 8-CI cAMP did not appear to be mediated through its toxic
adenosine metabolite. Interestingly, these site-selective analogues are
specific inhibitors of transformed cell proliferation rather than normal
cells. The growth inhibitory effect of these analogues on non-transformed
NIH/3T3 cells was only 15 - 30% of the growth inhibition demonstrated in
the transformed line (Cho-Chung et al., 1989). At concentrations that
effectively inhibit the transformed lines, these analogues have also been
shown to produce little (less than or equal to 10%) or no inhibition on
normal rat kidney cells (Tortora et al., 1989), normal mammary epithelial
cells, and normal blood lymphocytes (Cho-Chung, 1989). The micromolar
concentrations of site-selective analogues required to inhibit a wide
spectrum of cancer lines suggest that these site-selective cAMP
analogues may be useful as chemotherapy agents in the prevention and
cure of cancer. Using these more potent analogues compared to DBcAMP
and cAMP investigators have studied the molecular effects in an attempt
to understand the role of protein kinase A in cellular proliferation.
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cAMP Analogues Antagonise The Hormone Response:
As previously discussed, addition of DBcAMP can mimic the response
of oestradiol ablation in regression of the hormone-responsive DMBA-
tumour (Cho-Chung & Redler, 1977); the increased phosphorylation of
regression associated protein by cAMP was inhibited by addition of
oestradiol (Cho-Chung & Doud, 1978). In the same system, it was also
shown by Bodwin et al. (1978) that during regression of the tumour,
induced either by DBcAMP or ovariectomy, cAMP-binding activity
increased while oestrogen binding decreased in the cytosol and nucleus.
Furthermore, when DBcAMP treatment was ceased, or oestrogen was
injected into the mice, the opposite effect occurred: cAMP-binding
activity decreased and oestradiol binding activity increased. These
opposite effects between cAMP and oestrogen were not due to competition
for each others binding proteins (Bodwin et al., 1981). Alteration in the
oestrogen binding level by cAMP was also demonstrated in-vitro using
cultured endometrial and breast cells (Fleming et al., 1984). In addition to
these effects, cellular ras p21 was shown to decrease in regressing
tumours after hormone withdrawal (Huang & Cho-Chung, 1984).
Site-selective analogues were used by Katsaros et al. (1988) to
further investigate this apparent antagonism between cAMP and oestradiol
in the hormone-responsive breast cancer cell line MCF-7. Addition of 17(3-
oestradiol (10 nM) to MCF-7 cells resulted in an increase in cellular
proliferation of 2 to 3 fold over cells cultured in the absence of steroid.
This oestradiol stimulated proliferation was reduced by 40% after three
days with cells cultured in the presence of the oestrogen-antagonist
tamoxifen (1p.M). Addition of 8-Ci cAMP (10p.M) in the presence of
oestradiol resulted in a 70% growth inhibition of these MCF-7 cells after
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three days. The C-6 analogue, N6-Benzoyl cAMP (20pM), proved to be as
effective as tamoxifen (1 pM), however, combination of 8-CI cAMP (1pM)
and N6-Benzoyl cAMP (0.5pM) synergistically inhibited growth and stopped
cellular proliferation after three days. Katsaros et al. (1988) also
demonstrated that MCF-7 cells inhibited by 8-CI cAMP (2 pM) for 9 days
would eventually resume proliferating after drug removal. Addition of 8-
Cl adenosine or 6-mercaptopurine at the same concentration and duration
of exposure as 8-CI cAMP not only inhibited cellular proliferation, but
proliferation never resumed on removal of these agents.
ras p21 appears to play an important role in the control of
proliferation, thus, regulation of ras p21 expression in tumours by
oestradiol and cAMP may suggest a potential mechanism by which these
agents regulate proliferation. Katsaros et al. (1988) investigated the
effect of oestradiol and 8-CI cAMP on the expression of two oncogenes,
myc and ras. The protein products of the myc and ras oncogene remained
elevated in MCF-7 cells treated with oestradiol and tamoxifen. 8-CI cAMP
(10 pM), however, reduced the expression levels of both oncogenes; ras
p21 was reduced by 48% of the control after 3 to 4 days. Furthermore,
expression of ras p21 was reduced by 90% of control MCF-7 cells treated
directly with 8-CI cAMP (10 pM) without the supplement of added
oestradiol (Tagliaferri et al., 1988). This reduction in ras p21 was not
evident on addition of 8-CI adenosine. From these data, it was concluded
that the antagonism between tamoxifen and oestradiol was different from
that of 8-CI cAMP, since tamoxifen did not modulate expression of c-myc
and c-ras.
Regulation of oncogenes could be a potential method of controlling
proliferation of a cell, but precisely how oestrogen and cAMP control p21
expression is as yet unknown. Oestrogen appears to regulate the binding
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levels of cAMP, and cAMP regulates the binding levels of oestradiol
(Bodwin et al., 1978; Fleming et al., 1984). However, it is not known if
oestrogen or cAMP can directly regulate ras oncogene expression. The
level at which this antagonism takes place in the cell is also unclear. It
could occur either at the site of the gene promoter or alternatively earlier
on within the cytosol preventing the activation of a transcription complex.
It is unlikely that cAMP modulates oestradiol regulated expression of ras
p21 directly through antagonism alone, since cAMP analogues have been
effective at altering expression levels in non-hormone responsive cell
lines (Tagliaferri et at., 1988).
Molecular Events Associated With cAMP Analogues:
Tagliaferri et at. (1985) previously demonstrated that the
expression of ras p21 was inhibited in Harvey ras transformed mouse
fibroblast cells exposed to DBcAMP or 8-Br cAMP. This decrease in ras p21
expression was concomitant with a change in the cell phenotype to one
resembling a non-transformed cell. Furthermore, 8-CI cAMP was shown to
inhibit expression of p21 in non-hormone responsive breast cancer line
MDA-MB-231 and the LS-174T colon carcinoma line (Tagliaferri et al.,
1988; Katsaros et al., 1987). Ally et al. (1989) investigated the regulation
of oncogene expression in the lung xenograft LX-1 treated with 8-CI cAMP.
In the first 6 hours of exposure, mRNA levels of c-myc had decreased by
50% of the control, whereas, the N-ras message level had increased by
approximately two-fold. By seven days the level of both oncogene mRNA
levels were equally reduced below the level of controls, thus indicating
that the effect of 8-CI cAMP on reducing N-ras mRNA level was not via
direct modulation and probably required expression of other proteins to
26
affect the decrease. The initial increase in N-ras mRNA may have been a
direct effect, since, after only one hour, the level had increased to greater
than two-fold of the control. This may have been via increased gene
expression or stability of N-ras mRNA.
In addition to the modulation of oncogenes, other biochemical
changes have been reported in the presence of cAMP analogues. These
changes include induction of differentiation in leukaemic cells (Tortora et
at., 1988) and suppressed production of transforming growth factor-a
(TGF-a) in Kirsten ras transformed rat kidney fibroblast cells (Tortora et
a!., 1989).
Leukaemic cells appear to have lost the ability to mature and
instead continue to proliferate (Sachs, 1980). Tortora et at. (1988)
demonstrated that 8-CI cAMP could inhibit the growth of human leukaemic
cell lines, including HL-60 (acute promyelocytic) and Molt-4 (acute T
lymphocytic) between 5 - 20 jiM. These authors also determined that
incubating HL-60 cells for three days with 8-CI cAMP resulted in a marked
increase in the expression of monocyte-specific surface antigens that are
associated with maturation and a decrease in the markers associated with
immature cells. In addition, loss of nucleoli and a decrease in nuclear-to-
cytoplasmic ratio occurred, giving cells a phenotypic appearance similar
to mature cells.
TGF-a is a potent mitogen for fibroblasts and epithelial cells, and
its role has been considered in paracrine and autocrine growth of various
cancer cells (Derynck, 1988). As demonstrated by Tortora et al. (1989),
the production of TGF-a in 8-CI cAMP growth inhibited Kirsten ras
transformed rat fibroblast cells was suppressed, concomitant with a
decrease in ras p21 and a reversion of the transformed phenotype.
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Furthermore, it was observed that 8-CI cAMP could prevent
transformation of mouse mammary cells by TGF-a (Ciardiello et al.,
1990). Thus, there appears to be a multitude of biological changes that
occur in cancer cells treated with cAMP analogues, all of which may be
important factors in controlling proliferation.
Relative Expression Levels Of Type I and Type II
Kinase A:
The relative levels of the two types of kinase A have been
investigated the use of a number of techniques, including chromatography,
Scatchard analysis, antibodies, and photoactivated incorporation of 8-
azidoadenosine 3',5'-cyclic [32P] monophosphate (Corbin et al., 1975;
Sugden et al., 1976; Hofmann et al., 1977; Pomerantz et al., 1975). Studies
involving the use of these techniques on cancer cells revealed a
predominance of Rl over Rll levels, and in some lines the only detectable
subunit was Rl (Katsaros et al., 1987; Cho-Chung. 1989). These cell lines
include those that have been previously discussed during the course of
this introduction. Cells growth arrested or differentiated by addition of
site-selective cAMP analogues appear to have a decreased level of Rl and
an increased level of Rll (Katsaros et al., 1987; Cho-Chung. 1989). The
higher expression of Rl correlates with proliferating cells, while Rll
correlates with growth inhibited and differentiated cells. Studies in
primary tumours, however, are not as clear cut as for those of the cell
lines. Nevertheless, there are many reported cases of tumours having a
predominance of Rl over Rll. For example, a study by Eppenberger et al.
(1980) compared primary breast tumours with normal breast and showed
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significantly higher ratios of type I (Rl) to type II (R11) protein kinase.
Other studies for the same tissue type have revealed changes in the Rl :
Rll expression ratio (Handschin et a/., 1983)as well as an increase in Rl
(Weber et at., 1981). Moreover, a study of renal cell carcinomas measured
an increase in the type I : type II ratio by two-fold (Fossberg et al., 1978),
and another in Wilm's tumours showed a two times greater ratio of Rl : Rll
when compared to normal tissue (Nakajima et al., 1984).
Alteration in the ratio of type I and type II (or Rl and Rll) expression
does not appear to be a unique feature of cells with a malignant phenotype.
The relative content of type I and type II varies among normal tissues
(Corbin et al., 1975; Sugden et al., 1976; Hofmann et al., 1977).
Furthermore, developmental studies have also revealed that the relative
expression of both types of protein kinase A may play an important role in
tissue development and differentiation. Two studies in mouse heart
development showed that the ratio of type I : type II decreased by three¬
fold in hearts from 7 or 14 day olds to those from mature adults
(Malkinson et al., 1978; Haddox et al., 1979). These data suggest that Rl is
associated with the development phase of the mouse heart and Rll with
the increase in heart size. In rat testes the level of type I remained
constant during development, whereas, a seven-fold increase in type II
occurred between birth and 90 days of age (Lee et al., 1976). This increase
in type II coincides with the acquisition of the capacity for
steroidogenesis and spermatogenesis. A study of ovarian follicle
granulosa cell differentiation in hypophysectomised rats demonstrated
that injections of oestradiol and follicle stimulating hormone induced
differentiation (Jonassen et al., 1982). These treatments resulted in an
increased level by 10 to 20 fold of type II in the granulosa cells. Ventral
prostate, another steroid responsive tissue, also appears to have an
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increase in the levels of type I with a decrease in type II levels in the
presence of steroids (Richards & Rolfes, 1980). These tissue studies and
experiments with cell lines have led to the general view that Rl (or type I
protein kinase A) is involved in proliferation and that Rll (or type II
protein kinase A) is involved in growth arrest and differentiation.
Modulation Of The Regulatory Subunits:
Insight into the 8-CI cAMP-induced regulation of cancer growth
became clearer with the availability of antibodies specific for the
different regulatory subunits. Ally et al. (1988) used specific antibodies
for Rl, Rlla, and Rllp to study the early events associated with addition of
8-CI cAMP. Using the LS-174T colon carcinoma line, these authors
observed a rapid translocation of the Rllp subunit from the cytoplasm to
the nucleus. This translocation was a very rapid event occurring in ten
minutes. They also used a nuclear run-off transcription assay to
determine the transcriptional activity of the regulatory and catalytic
subunit genes on exposure of 8-CI cAMP. After one hour there was no
apparent change in the transcriptional activity of the catalytic or RIla
subunit. However, Rl levels dropped to 50% after a one hour exposure to 8-
Cl cAMP, and this change was not detectable in the first 30 minutes.
Moreover, transcriptional activity of the Rllp gene increased by two-fold
after only 30 minutes. Interestingly, Alley et al. (1988) also found that 8-
Cl cAMP, though it has a higher affinity for the Rll subunit, had a three¬
fold greater activation of type I kinase A. Although, N6-butyryl cAMP has a
higher affinity and activation for type I compared to 8-CI cAMP, this
analogue had little or no effect on proliferation of the LS-174T cells
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(Katsaros et al., 1987). These data suggest that kinase activity was not
the determining factor for the cellular response of LS-174T cells, but
that the Rllp subunit was the key to the growth regulatory action of cAMP.
The involvement of the Rla and Rllp regulatory subunit has also been
investigated with the use of antisense techniques. Antisense sequences,
which are complementary to the mRNA sequence (either synthesized from
DNA or RNA), can prevent translation of the message (Rothenberg et al.,
1989). Hybridisation of the complementary strand produces a duplex that
is believed to be prone to digestion and this prevents translation of the
mRNA (Paterson et al., 1977). This technique, therefore, enables the
selective removal of a species of mRNA from the cell, effectively
inhibiting de novo synthesis of that protein. Using this approach, Tortora
et al. (1990) employed a 21-mer oligodeoxynucleotide complementary to
the R11 p mRNA to determine its involvement in the growth of the
leukaemic cell line HL-60. Exposure of cells to the RlIp antisense sequence
(15 pM) for seven days had no effect on the rate of cellular proliferation.
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8-CI cAMP (10 pM), in the absence of oligomer, inhibited proliferation by
70% and produced a morphological change. However, in the presence of
oligomer, 8-CI cAMP reduced the level of proliferation by only 20% and no
change in morphology was evident. No detectable Rllp protein was found in
the presence of oligomer, and 8-CI cAMP could not induce levels of Rllp.
This work gave direct evidence that Rllp regulatory subunit is required for
the growth inhibitory effect and differentiation of HL-60 cells. Tortora et
al. (1991) performed the same experiments using the Rla antisense
sequence on HL-60 cells. They demonstrated growth inhibition and
monocyte differentiation with antisense Rla (15 pM) alone, a typical
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response observed with 8-CI cAMP. No further change in growth inhibition
and cellular morphology was observed on addition of 8-CI cAMP to cells
treated with oligomer. Furthermore, cells treated with antisense Rla had
decreased levels of Rla protein, concomitant with an increase in the Rllp
product. Tortora et al. (1991) also showed that the growth inhibition and
differentiation of HL-60 cells by phorbol esters was not affected by
addition of antisense regulatory subunits. Their data suggest that the
mechanism of action of 8-CI cAMP with HL-60 cells is independent of that
of phorbol esters.
cAMP Response Elements:
The Rllp subunit shares extensive homology with the cAMP receptor
protein (CRP) or catabolite activator protein (CAP) in bacteria. CAP is a
positive activator of the lac operon and is only active in the presence of
cAMP. The activated CAP binds upstream of the lac promoter facilitating
the formation of an active initiation complex (Ullman & Danchin, 1983). In
light of accumulating data, Rllp is strongly implicated as a trans-acting
factor.
CAP, and possibly Rllp, can directly modulate gene expression in the
presence of cAMP through binding to specific DNA-binding sites, called
cAMP response elements (CRE). There have been several cAMP-regulated
genes identified in mammalian cells, that include chorionic gonadotropin
(Silver et al., 1987), somatostatin (Montminy et al., 1987), and
proenkephalin (Comb et al., 1986). Within the first 150 base pairs of the
5'-flanking region of these gene promoters an eight base pair palindromic
sequence was identified as the functional cAMP response element. A
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chimeric construct of the DNA sequence containing the CRE sequence from
the chorionic gonadotrophin was shown to confer cAMP inducibility to a
heterologous promoter (Silver et al., 1987). Furthermore, deletion studies
of the 5'-flanking sequence and chimeric constructs with non-cAMP
responsive genes have established this sequence as a cAMP responsive
element (Short et al., 1986; Montminy et al., 1987; Comb et al., 1986).
Another cAMP-responsive element has been identified in the SV40 and
human metallothionein 11 a promoters (Imagawa et al., 1987), termed
Activator Protein 2 (AP-2). This element is not exclusively induced by
cAMP, but also by phorbol esters. Addition of both agents have an additive
effect on transcription of the gene (Mitchell et al., 1987). Other genes
identified with an AP-2 sequence include growth hormone (DeNoto et al.,
1981), prolactin (Cooke et al., 1982), and plasminogen activator (Nagamine
et al., 1984).
Characterisation of these DNA sequences has enabled researchers to
identify the nuclear binding proteins that associate to them. Montminy et
al. (1987) purified a CRE binding protein (CREB) for the somatostatin gene
which bound specifically to a 30 base pair sequence that contained the
CRE. The protein had a molecular weight of 43 kDa and was phosphorylated
in-vitro by the catalytic subunit of kinase A. The phosphorylation of this
protein, however, did not alter the binding affinity for the CRE. Study of
another CREB protein, which regulates the human chorionic gonadotrophin
gene, also had no increase in binding affinity when phosphorylated
(Delegeane et al., 1987). Furthermore, the binding affinity of AP-2 protein,
identified for the metallothionein IIa gene (Imagawa et al., 1987), for its
DNA element was not affected in the presence of cAMP. cAMP does not
appear to affect the binding affinity of CREB and AP-2 proteins to their
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respective regulatory elements in genes studied so far (Roesler et al.,
1988). Work by Nakagawa et al. (1988) provided strong experimental
evidence suggesting the involvement of the kinase A catalytic subunit on
gene transcription. Using the urokinase-type plasminogen activator gene,
they demonstrated that in an in-vitro transcription assay the catalytic
subunit stimulated transcription of this gene to a greater extent than
cAMP. Grove et al. (1987) also indirectly implicated the importance of the
catalytic subunit in transcription. These authors transfected a gene coding
for a catalytic subunit inhibitor into cells which were also transfected
with a cAMP-inducible gene. In this system, 90-95% inhibition of the
induction of the cAMP-responsive gene by cAMP was reported. This
evidence supports the role of the catalytic subunit as an intermediate in
the effect of cAMP on gene transcription. Yamamoto et al. (1988) used a
nuclear extract from PC12 cells to study the in-vitro transcription of a
somatostatin-CAT fusion gene which contained an intact CRE. The nuclear
extract was cleared of CRE binding protein using a CRE-affinity column,
which allowed the authors to directly study a purified 43 kDa CREB
protein (Montminy et al., 1986). The technique of gel retardation, used to
detect protein-DNA complexes, identified two bands that could be
competed out by CRE sequences. Moreover, the higher molecular weight
complex had a ten-fold greater affinity than the lower molecular weight,
and was characterised and found to be a dimer of the CREB protein. This
protein bound to the CGTCA sequence of the palindromic CRE sequence on
each side of the DNA to form the dimer. Phosphorylation of the CREB
proteins appeared to be important for the formation of the dimer, since
treatment of CREB with alkaline phosphatase substantially reduced the
levels of dimer formed. The CREB protein was also shown to be
phosphorylated by kinase A and kinase C, but only kinase C appeared to
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cause an increase in formation of the dimer. Moreover, kinase A treatment
induced transcription by twenty-fold. Unfortunately, the effect of kinase
C on transcription could not be confirmed because of technical problems.
Nevertheless, these data suggest a possible dual regulation for CRE-
dependent transcription between kinase A and kinase C. Cambier et al.
(1987) showed that on addition of cAMP to B lymphocytes, kinase C
translocated to the nucleus. This translocation appeared to be specific for
cAMP and would support the suggestion of dual regulation by kinase A and
kinase C. However, the translocation of kinase C in PC12 cells was not
shown. Lamph et al. (1990) suggested that CREB could function as a
negative regulator. The c-jun promoter contains a CRE sequence and the
gene is induced by serum or forskolin. Addition of CREB represses the
expression of c-jun on addition of serum to the cells and can be removed
by phosphorylation of the CREB protein with kinase A or forskolin. This
suggests that CREB protein could have a dual role in controlling the
transcription activity of cAMP-responsive genes.
R11p appears to be involved in the modulation of gene expression of
cancer cells which results in growth inhibition and differentiation.
Mednieks et al. (1989) demonstrated, with malignant cell lines treated
with 8-CI cAMP, that nuclear and cytoplasm extracts added to synthetic
DNA containing CRE sequences had increased protein binding activity.
Though 8-CI cAMP results in the translocation of Rllp to the nucleus, these
data do not prove that it is directly involved in DNA binding. However, Rll
has been shown to bind to chromatin (Jungmann et al., 1986; Sikorska et
al., 1988). Furthermore, it also binds to DNA in-vitro, as has been
demonstrated by Constantinou et al. (1985), who suggested that the
protein had properties of a topoisomerase. Direct binding of Rll to duplex
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DNA has also been demonstrated by Wu & Wang (1989)- These are the only
evidence, to date, that suggests that Rll can directly interact with DNA.
To investigate the role of Rllp in regulaion of CRE containing genes,
Tortora & Cho-Chung (1990) stably transfected cAMP-unresponsive mutant
pheochromocytoma cells (A126-1B2), which lack type II kinase A, with
the Rllp gene. These cells were then transfected with a somatostatin gene
construct linked to a reporter gene. Expression of the Rllp construct in
these cells now conferred transcription activity of the somatostatin gene
construct in the presence of cAMP. Therefore, Rllp expression could confer
cAMP responsiveness to a cell that was characterised as being deficient
in type II kinase only. Expression of Rla could not confer cAMP induced
gene expression of the reporter gene in these mutant cells. These data
suggest a direct involvement of Rllp in expression of genes with a CRE in a
cAMP-dependent manner. It was therefore concluded that the Rllp was
essential for activation of the CRE-containing construct and that the
regulatory subunit of type I was not. This evidence does not appear to
support the previous view of researchers that the catalytic subunit is
involved in gene transcription of this somatostatin construct, since these
cells still have type I kinase A activity. It is possible that active type I
kinase plus the presence of Rllp is required for transcriptional activation.
It is also possible that CRE-regulated transcription may involve the
interaction of CREB and Rllp with transcriptional activity regulated by
kinase A and kinase C. CREB appears to have a dual function depending on
its state of phosphorylation, acting as a repressor or activator. It does
seem likely that the Rllp subunit, which can also be phosphorylated by
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kinase A (Taylor et al., 1988), could have the potential for dual regulation
of transcription in a similar manner as CREB. However, this has yet to be
established.
Overview:
Site-selective analogues do appear to be a powerful tool for the
control of malignant growth. There is accumulating evidence for the
mechanism of action that clearly implicates a complex interaction of
biochemical agents, including oestrogen receptors and kinases. Antisense
work does suggest that R11p and Rla are involved in the control of
proliferation, but their role in cAMP-responsive gene induction is still not
clear. Furthermore, studies of cAMP-responsive genes have been
investigated in studies using addition of cAMP or forskolin, an activator
of adenylyl cyclase, however, it would be interesting to know the effect
cAMP analogues have on the expression of these genes and the effect these
genes have on proliferation. 8-CI cAMP has been shown to modulate
oncogene, growth factor, differentiation markers, RlIp, and Rla expression.
These expression events have not been fully characterised in terms of
when expression occurs on addition of 8-CI cAMP, apart from RIlp which
does appear to be an early event. A better understanding of the order genes
are expressed on the addition of 8-CI cAMP may give insight into its
antiproliferative mechanism. It does seem likely that, since 8-CI cAMP
can replace cAMP for the activation of kinase A, it could also activate
CREB and AP-2 proteins. It would, therefore, be important to understand
the effect these cAMP-responsive gene products have on proliferation, and
by doing so, verify if the effects of 8-CI cAMP are indeed due to Rllp,
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CREB, AP-2 or combination of these three proteins. Understanding of the
complex cascades that take place on addition of cAMP or cAMP analogues
will help to identify the key components involved in control of
proliferation and this, in turn, could lead to future development of other
therapeutic agents.
INITIAL AIM OF THE THESIS:
The initial aim of this thesis is to investigate the mechanism of 8-
Cl cAMP growth inhibition, especially in the hormone-responsive breast
cancer line MCF-7. 8-CI cAMP was reported by Katsaros et at. (1988) to
antagonise the oestradiol growth stimulation of these cells, and this
inhibition in growth was also associated with a decrease in the level of
p21 and the Rl : Rll expression ratio. This investigation intends to
elucidate how 8-CI cAMP and oestradiol control the expression of p21, and
determine if the concentration of p21 is involved in control of






The following materials were obtained as indicated.
1.1 Radiochemicals:
From Amersham Internationa! pic, U.K.;
- Protein A, 125l-labelled with Bolton and Hunter reagent
(specific activity >1.11 GBq/mg total protein A)
- [methyl-3H] Thymidine containing 2% ethanol (specific activity
1.81 TBq/mmol)
From ICN Radiochemicals, U.S.A.;
- [32p] 8-Azidoadenosine-3':5' cyclic monophosphate (specific
activity 40-60 Ci/mmol);
1.2 Gel Electrophoresis:
Where ever possible Electrophoresis Purity Reagents were used.




- Piperazine Diacrylamide (PDA)
- N,N,N\N'-Tetramethylethylenediamine (TEMED)
From Sigma Chemical Co. Ltd., U.K.;
- (Coomassie)Brilliant Blue R
- Bromophenol Blue
- Glycine







From Sigma Chemical Co. Ltd., U.K.;
- Anti-Actin (polyclonal)
- Anti-Rabbit IgG (whole Molecule)
- Anti-Rat IgG (whole Molecule)
- Anti-Tubulin (polyclonal)
Supplied by the I.C.R.F. Antibody Production Unit;
- BA17 (5 mg/ml total protein) monoclonal antibody against
cytokeratin 19




1. 4 General Chemicals:
These reagents are of Analar grade or equivalent.




From Koch-Light Laboratories Ltd;
- Isopropanol
From May & Baker Ltd.;




- Nonidet P 40 (NP40)
- Potassium Dihydrogen Orthophosphate (Aristar™)
- Sodium Chloride
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- Sodium Hydroxide Pellets
From Sigma Chemical Co. Ltd., U.K.;
- Ammonium Sulfate
- Charcoal, activated
- Deoxycholic Acid, sodium salt
- Ethylenediaminetetra acetic acid (free acid)
- Magnesium Chloride, Hexahydrate
- 2[N-Morpholino]ethanesulfonic Acid
- Tetrabutylammonium Hydroxide
From Rathburn Chemical Ltd.;
- Methanol (HPLC grade)




From Sigma Chemical Co. Ltd., U.K.;
- Aprotinin





- Insulin (from Bovine Pancreas)
- Napthol Blue Black
- Phosphodiesterase, 3':5'- cyclic nucleotide from bovine heart
- Retinoic acid (All Trans)
- Ribonuclease A (Bovine Pancreas)
- Sodium Selenite
- Sulfatase Type IV
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- Transferrin (Human)
Kindly supplied by Dr Y.S. Cho-Chung, National Institutes
Health, Bethesda, U.S.A.;
- 8-chloro adenosine 3':5'-cyclic monophosphate
From Pharmacia LKB.;
- Dextran T70
- Sephacryl S-200 (Superfine);
From Amersham International pic, U.K;




Kindly supplied by the Imperial Chemical Industries, pic.;
- Tamoxifen
From Premier Brands, U.K. Ltd.;




- X-RAY FILM Developer
- X-RAY FILM Fixative
From FUJI PHOTO CO. Ltd.;
- Fuji X-RAY FILM
From Genetic Research Instrumentation Ltd.;
- X-ray Film Cassettes with Intensifying Screens
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1.7 Cell Lines:
Supplied by the Michigan Cancer Foundation, U.S.A;
- Michigan Cancer Foundation 7 (MCF-7) epithelial breast cancer
cell line
Supplied by the Imperial Cancer Research Fund, London;
- PE01 epithelial ovarian cancer cell line
- HT-29 colorectal cancer cell line
- MDA-MB-231







- Dulbecco's Modified Eagle Medium with sodium pyruvate,
with 1000mg/L glucose
- Dulbecco's Modified Eagle Medium without phenol red, with
sodium pyruvate, with 1000mg/L glucose
- NewBorn Calf Serum
- RPMI with L-glutamine
- RPMI with L-glutamine, without phenol red
- Trypsin Solution 0.25% in Gibco solution A
- Penicillin (10000 lU/ml) - Streptomycin (10000 pg/ml)
solution
From Becton Dickson and Company;
- Syringes and needles
- 25 cm2, 75 cm2, 175 cm2 Tissue Culture Flasks
From Northumbria Biologicals Ltd.;
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- Foetal Calf Serum
From Sigma Chemical Co. Ltd., U.K.;
- L-Glutamine
From Flow Laboratories.;
- Phenol Red 0.5% solution
From OXOID Ltd.;
- Phosphate Buffered Saline (Dulbecco 'A')
From Costar;
- 6 well tissue culture clusters
From J.Bibby Scientific Products Ltd.;
- 96 well flat bottom plates;
From Sterilin;
- 30 ml Universal containers and 7 ml Bijou bottles
1.9 Non-Chemicals:
From Bio-Rad Laboratories Ltd.;
- Trans-Blot Transfer Medium (0.45pm)
- Filter Paper Backing
From Schleicher & Schuell;
- Cellulosenitrat(E) 0.2pm
From Whatman Limited;
- Filter Paper no.1
- GF/B glass fibre paper
- Cellulose Nitrate 0.2 pm
From Millipore Corporation;
- Durapore Membrane Filter 0.45 pm
- GS 0.22 pM Filter Unit
From Amicon;







2.1.1 Routine Maintenance of Cell Lines:
Culturing of cells was carried in a Class II hood and only sterile
glass ware, plastics and solutions used.
All cell lines were routinely maintained in monolayer culture
at 36.5 oc under an atmosphere of air/C02 (95%/5%). MCF-7,
MDA-MB-231, HT-29, NIH/3T3 v-ras, RFHO 6N1 and RFHO 208F
were cultured in 175 cm2 and 75 cm2 tissue culture flasks with
Dulbecco's Modified Eagles Medium (DMEM) containing phenol red,
supplemented with 2 mM glutamine and 10% (v/v) foetal calf
serum (FCS) heat inactivated at 56 oc for 30 minutes. PE01 and
PE04 cells were cultured in RPMI 1640 containing phenol red plus
the other supplements as detailed above. All FCS used for routine
passaging of cells and experiments was heat inactivated.
Every six or seven days confluent monolayers of cells were
passaged into new flasks with fresh phenol red medium
containing 10% FCS (v/v); this was done as follows:
- Old medium was discarded and the cell monolayer washed
with a volume of PBS (a volume refers to enough liquid to
cover the surface with an approximate depth of 0.5 cm).
- For MCF-7 cells a volume of 1 mM EDTA in PBS was put on the
monolayer at room temperature, then removed after 5 minutes;
this assisted the removal of the monolayer.
- A volume of 0.25% trypsin solution/versene (1 mM EDTA in
PBS plus 0.5% (v/v) phenol red) [1:1]) was placed on the
monolayer until it detached from the plastic.
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- Fresh phenol red medium containing 10% FCS (v/v) (10 ml)
was used to pipette the detached cells up and down against the
side of the flask to break up cell clumps.
- A small volume of the cell suspension was then added to a new
flask containing fresh medium containing supplements.
(Total volume: 25 cm2= 5 ml, 75 cm2= 20 ml, 75 cm2= 50 ml)
2.1.2 Mycoplasma Testing:
Once a month, medium (5 ml) was removed from confluent
flasks of cells and tested for the presence of mycoplasma
contamination (Barile, 1973) courtesy of Bill Christie, M.R.C.
Human Genetics Unit, Edinburgh.
2.1.3 Banking Cells and Recovering:
Routinely, confluent flasks of cell were harvested by
trypsinising of the monolayer of cells (section 2.1.1). The
solution of cells was then aseptically transferred to a universal
container and pelleted at 1000 g for 10 minutes. The liquid was
removed and the pellet of cells resuspended in new born calf
serum : dimethyl sulfoxide (1:1) with 1 ml for approximately
every 107 cells. The mixture was then aseptically transferred to
a ciyestat tube and placed in liquid nitrogen storage banks.
Cells were recovered by removing a cryostat tube and thawing
the mixture. This mixture was then aseptically washed with PBS
by repeated resuspension of the cell pellet with PBS and further
centrifugation. This procedure was repeated three times before
the cell pellet was finally resupended in fresh medium containing
supplements and transferred to a tissue culture flask (25 cm2 or
75 cm2). Recovery of the cells would take 1-3 weeks, during that
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period of time the cells were frequently washed with PBS and
fresh medium and supplements added.
2.1.4 Plating Cells For Experiments:
A flask of cells were trypsinised from the plastic according to
section 2.1.1. The cell suspension was transferred to a sterile
universal container and syringed four times against the wall of
the tube using a 21G11/2 needle. This produced a single cell
suspension that could then be counted using a haemocytometer or
Coulter counter™ (Coulter Electronics; see section 2.1.5 for
settings) to determine the cell number per millilitre. An aliquot
of cells was added to a volume of fresh medium with phenol red
and 10% FCS (v/v), so that a volume for a given well would yield
the correct number of cells when dispensed. This number would
depend on the size of well used. For example, 6 well plates had 2
ml dispensed per well with approximately 5 x 104 cells per
millilitre of medium to give 105 cells per well; 96 well plates
received a volume of 250 pi with 4 x 104 cells per millilitre
giving a final cell count of 104 cells per well.
After a period of 18-24 hours to allow attachment of the cells
to the plastic, the phenol red containing medium was aspirated
off and replaced with fresh, phenol red free medium supplemented
with 1% FCS (v/v) or HITS*. This growth medium was also
supplemented with penicillin (100 I.U./ml) and streptomycin (100
jLtg/m I).
of
'Experiments involving the use medium containing HITS had cells
washed with HITS medium (section 2.2.1) only.
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24 hours later, the medium was aspirated off and fresh phenol
red free medium containing the appropriate supplements added to
each well (see individual experiments). A set of wells were
counted (see section 2.1.5) to determine the initial cell number
per well before the addition of drug to each well. Every two or
three days, old medium was aspirated off and fresh medium
containing the appropriate supplements and drug added.
2.1.5 Counting Plated Cells:
At desired time intervals, medium was aspirated from the
wells and a volume of 2.5 mM EDTA in PBS was added. PE01 and
PE04 cells where not detached with this solution but with 1 mM
EDTA in PBS/trypsin-versene solution (1:1). The solution was
incubated on the cells for 15 to 30 minutes to allow the cells to
detach from the plastic. The cells were broken into a single cell
suspension using a 21G11/2 needle by syringing the cells against
the wall of the well 4-5 times. The presence of a single cell
suspension was checked under the inverted microscope
(Olympus). 200 pi of this single cell suspension was added to a
pot containing 9.8 ml of 0.9% (w/v) sodium chloride. Cell number
was determined using a Coulter counter ZM with a 140 pm orifice
and a sampling volume of 0.5 ml per count. The analyzer settings
were such that the cell numbers determined by Coulter counter
were similar to that of the haemocytometer. The reading from the
counter was multiplied by 100 to convert the figure into cell
number per millilitre.
Cell No./ml = [analyzer count] x [pot volume/sample volume] / sampling volume
= [analyzer count] x [10ml/200pl] / 0.5ml
= [analyzer count] x 100
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The cell number per well was calculated from cell number per
millilitre multiplied by the volume of the solution used to detach
the cells from the well. Three counts were determined for each
pot (i.e. for each well).
2.1.6 Thymidine Uptake Experiments:
96 well plates were set up according to section 2.1.4. For
example, MCF-7 cells were plated at approximately 104 cells per
well. 72 hours after medium and drug were added, each well
(containing 200 pi) received 50 pi of 0.37 MBq [methyl-3H]
thymidine per millilitre of washing medium (medium used to
wash off the phenol red medium after plating cells; see section
2.1.4). The plates were returned to the incubator for 6 hours. The
radioactive waste medium was removed and the wells rinsed with
ice cold PBS. Each well received 100 pi of trypsin/versene
solution for approximately 30 minutes to detach the cells. The
amount of [methyMH] thymidine incorporated into DNA was




All solutions were prepared using double distilled, deionised





Sodium Selenite 30 nM
These reagents were added to phenol red free media to give the
above concentrations.
2.2.2 Buffer 10: 2.2.3 Buffer A:
0.1 M Sodium Chloride 20 mM Tris
0.5%(w/v) Sodium Deoxycholic acid 0.25 M Sucrose
20 mM Tris.HCI (pH 7.4)
5 mM Magnesium Chloride
2 KlU/ml Aprotinin
1% (v/v) NP40
2 mM Magnesium Chloride












30 mM Tris (pH 6.8)
30% (v/v) Glycerol







2.2.7 NTE-NP40: (pH 7.5)
50 mM Tris




2.3 PREPARATION OF CELL EXTRACTS
All procedures were performed at 0-4 OC.
2.3.1 Lvsate:
Cell lysates were prepared using the detergent based Buffer 10
to enable the membrane associated proteins to be extracted into
solution (Collins & Salton, 1979). Cells were collected from
flasks, and cell number per ml determined (section 2.1.5). The cell
suspension was centrifuged at 750 g for 10 minutes at 4 oq and
the pellet resuspended with ice-cold PBS then re-centrifuged. A
volume of Buffer 10 was added to the cell pellet (250 pi Buffer
10 per 107 cells) and then sonicated using a micro ultrasonic cell
disrupter (KONTES) for two 15 second periods, the sample was
returned to ice between each period. The cell suspension was left
on ice for 30 minutes and then centrifuged at 100 000 g for 30
minutes at 4 oc. The resulting supernatant was used as a cell
lysate and the pellet kept for acid soluble protein extraction (see
section 2.3.2).
2.3.2 Acid Soluble Protein Extraction:
A volume of 0.2 M hydrochloric acid (200 pi per 107 cells) was
added to the pellet that remained after preparation of the cell
lysate (section 2.3.1). The pellet was vortexed vigorously until it
dissolved. The suspension was centrifuged at 100 000 g for 30
minutes at 4 °C. The supernatant was then removed and
neutralised using a solution of sodium hydroxide (final volume
250 pi per 107 cells).
All extracts were used fresh or stored at -40 oc.
54
2.3.3 Cvtosol:
The same procedure described for lysates (section 2.3.1) was
used to prepare cytosols, except the non-detergent Buffer A was
used instead of Buffer 10.
All extracts were used fresh or stored at -40 OC.
2.4 BRADFORD ASSAY (Bradford, 1976)
Protein concentration of cell extracts was determined using
the Bradford Assay Kit (Bio-Rad Laboratories). The kit was
used as a microtitre assay requiring only 10 pi of sample volume
for protein determination. A known protein concentration of
bovine serum albumin (supplied with kit) was used to construct a
standard plot of nine concentrations (0 - 1.4 mg/ml) from which
protein concentration of samples could be determined. Samples
and standards were loaded into a 96 well plate and absorbance at
600 nm determined using a 96 well ELISA Plate Reader (Bio-Rad
Laboratories). Construction of the calibration plot and
determination of protein concentration was performed using the
computer package AssayZap™ (Biosoft, U.K.).
2.5 POLYACRYLAMIDE GEL ELECTROPHORESIS (PAGE)
2.5.1. Preparation of Samples:
1/2 volume of sample buffer was added to a volume of cell
extract containing 50-120 pg of protein. The mixture was heated
to 95 °C for 3 minutes to denature the proteins. The mixture was
allowed to cool before centrifuging in a micro-centrifuge for one
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minute. Each sample was applied using a Hamilton syringe into a
well in the stacking gel (see section 2.5.2). In addition to the
samples, a volume of Rainbow™ markers (10 jj.l) was also
prepared and applied to the gel as described.
2.5.2 Gel Set Up And Running:
SDS-PAGE (Laemmli, 1970) was performed using the Protear?M
II Slab Gel (Bio-Rad Laboratories) connected to an
Electrophoresis Power Supply EPS 500/400 (Pharmacia). The
resolving gels were constructed using 12% or 7.5% (w/v)
Acrylamide : 0.32% or 0.2 % (w/v) PDA solution, respectively and
0.375 M Tris (pH 8.85) and 0.1% (w/v) SDS. This was mixed
together in a conical flask, then 0.025% (w/v) ammonium
persulphate and 0.025% (v/v) TEMED were added just prior to
pouring the gel. To ensure that the surface of the resolving gel
set horizontally a layer of water saturated butan-1-ol was placed
on top after pouring the gel. The gel was allowed to polymerize
for 30-60 minutes. The butanol was washed off the resolving gel
with distilled water. A teflon well forming comb was inserted
and the stacking gel solution containing 3.6% (w/v) Acrylamide :
0.1% (w/v) PDA solution, 0.125 mM Tris (pH 6.8), 0.1% (w/v) SDS,
0.025% (w/v) ammonium persulphate and 0.025% (v/v) TEMED was
poured. After polymerization, the comb was removed and the
wells rinsed out with tank buffer. The plate, containing the gel,
was assembled and tank buffer added to the bottom and top
reservoir. The wells were then loaded with prepared samples. The
samples were run through the stacking gel at 70 mA and then 35
mA through the resolving gel. The run was completed when the
Bromophenol blue dye reached the bottom of the resolving gel. The
apparatus was then dismantled and the stacking gel removed from
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the resolving gel.
The resolving gel could then be stained with Coomassie blue
dye (see section 2.5.4) to visualise proteins or assembled in an
electrotransfer tank to transfer protein to nitrocellulose (see
section 2.5.5) or dried down (see section 2.5.3).
Non-denaturing gels were constructed without the use of SDS
either in the gel or the sample buffer.
2.5.3 Gel Drvina:
The resolving gel was soaked in a solution of 10% (v/v)
glycerol, 10% (v/v) acetic acid and 40% (v/v) methanol for 45
minutes or overnight. The gel was then dried using a gel drier
(Pharmacia) connected to a vacuum pump. The drying process
took 2 hours.
2.5.4 Staining Gels:
Gels were immersed in a filtered solution of 40% (v/v)
methanol, 10% (v/v) acetic acid and 0.25% (w/v) Bromophenol
blue R overnight. Destaining was performed with 25% (v/v)
methanol and 10% (v/v) acetic acid with the addition of
diethylaminoethyl sephadex (0.2-0.5 g per 250 ml of destaining
solution). Destaining took approximately 6 hours.
2.5.5 Electrotransfer:
The resolving gel was soaked in transfer buffer for 10
minutes. A sheet of nitrocellulose was soaked in distilled water
for 10 minutes followed by a 10 minute soak in transfer buffer.
The gel and nitrocellulose sheet were assembled into a
cassette and immersed into the Trans-Blot™ cell
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(Bio-Rad Laboratories) containing transfer buffer. Transfer
was conducted at 4 oc, 60 volts with no current limit overnight.
The apparatus was disassembled and the nitrocellulose sheet
soaked in NTE NP40 buffer for 10 minutes at room temperature.
2.6 WESTERN BLOTTING (Burnette. 1981)
2.6.1 Western Blotting:
After electrotransfer (section 2.5.5) the nitrocellulose was
transferred to NTE NP40 containing 3% (w/v) Marvel at 37 oc for
3 hours. The nitrocellulose was then incubated in fresh 3% (w/v)
Marvel in NTE NP40 containing 10 pg/ml Y13-259 at 4 oc for 16
hours. After washing the nitrocellulose for two 10 minute periods
at 4 oc with ice-cold NTE NP40 the second antibody, rabbit anti-
rat IgG, was incubated on the blot in fresh 3% (w/v) Marvel in NTE
NP40 at a concentration of 4 jig/ml for 90 minutes at 4 oc. The
nitrocellulose blot was washed for a further two 10 minute
periods at 4 oc before [125l] Protein A in fresh 3% (w/v) Marvel in
NTE NP40 (25 kBq/ml) was added to the nitrocellulose and
incubated at 4 oc for 45 minutes. The blot was given a further
two 10 minute washes of NTE NP40 at 4 oc and air dried. The
nitrocellulose blot was wrapped in clingfilm and exposed to X-ray
film (see section 2.8) to detect binding of the antibody to p21.
2.6.2 Other Antibodies Used For Western:
Primary antibodies included:- monoclonal anti-tubulin,
polyclonal anti-tubulin, polyclonal anti-actin and monoclonal anti-
cytokeratin 19.
The secondary antibodies used were IgG molecules V
impiano^\eb-w»ithe host species used to produce the primary antibody.
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2.6.3 Staining Nitrocellulose Blots:
A nitrocellulose blot wasircmersed in a solution of 0.1% (w/v)
Naphthol blue black, 25% (v/v) isopropanol and 10% (v/v) acetic
acid for 30 seconds. The blot was destained with two volumes of
25% (v/v) isopropanol and 10% (v/v) acetic acid for one hour each
wash and then allowed to air dry.
2.7 PHOTOAFFINITY LABELLING (Pomerantz et a/., 1975)
4 x 10-7 M [32P] 8-Azidoadenosine-3':5' cyclic monophosphate
in an solution containing 0.27 M 2[N-morpholino]ethanesulfonic
acid and 53 mM magnesium chloride was added to 50-150 p,g
cytosol protein (section 2.3.3). The mixture was incubated at 20
°C for 60 minutes in the dark. The reaction mixture was then
irradiated for 15 minutes at 254 nm using a Universal UV Lampe
(Camlab). The mixture was then prepared for loading (section
2.5.1) onto a 12% SDS-PAGE gel (section 2.5.2). The gel was dried
(section 2.5.3) and then exposed to X-ray film (section 2.8).
2.8 AUTORADIOGRAPHY
2.8.1 Autoradiography: (Sambrook et at., 1989)
Two types of X-ray film were used, X-OMAT, which was the
most sensitive, and FUJI. Both types of film were preflashed first
before placing the film next to the gel or nitrocellulose.
Preflashing X-ray film using a flash unit covered in safety light
filter (Kodak, Wratten 22A) and filter paper (to reduced the
brightness of light flashed at film) sensitises the silver
halide crystals making it more sensitive to the radioactivity
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(Laskey & Mills, 1977). The required distance between the film
and the flash unit was determined by varying the distance and/or
changing the amount of filter paper covering the flash unit.
Preflashed and unexposed (unflashed) film was then developed and
pieces placed into a dual beam spectrophotometer at 545 nm
(Phillips). The correct distance was determined when the
absorbance reading was between 0.1-0.15.
Autoradiography was carried out at -70 °C for varying lengths
of time until an adequate intensity of staining developed to
enable scanning.
Example of exposure times:-
[125|] Protein A = 2-8 hours
[32p] 8-Azido cAMP = 2-24 hours
X-ray film was developed for 3 minutes in a 25% (v/v)
developer solution and then for 1 minute in a 25% (v/v) fix
solution. The X-ray film was washed in water for 10 minutes
before being air dried.
2.8.2 Autoradioaraph Scanning:
Scanning was performed on a non-commercial, pixel density
analyzer constructed by Daryl K. Green Medical Research Council,
Edinburgh. Staining densities were computer generated and the
area under the peak determined to give a quantitative figure in
arbitrary units.
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2.9 CHARCOAL STRIPPING SERUM (Lippman eta!., 1976)
2.5 g of charcoal was added to 100 ml of distilled water and
mixed for 5 minutes. The charcoal was allowed to settle and the
fines floating on the surface were removed using a dry piece of
filter paper. This mixing and removing was repeated until all the
fines were removed. 0.25 g of dextran was added and mixed
followed by addition of Tris to bring the volume to a final
concentration of 0.01 M. The pH of the solution was adjusted to
7.4 using HCI and then centrifuged at 25 000 g for 10 minutes to
produce charcoal/dextran pellets. 500 ml of FCS was incubated
with a 1000 units of sulphatase for 2 hours at 37 °C. This was
then added to the charcoal/dextran pellet. The mixture was
incubated at 56 °C for 30 minutes and centrifuged at 25 000 g for
10 minutes. The FCS was carefully removed from the pellet and
then added to another charcoal/dextran pellet prepared as
detailed above. This was then mixed for 16 hours at 4 oc. The
mixture was then centrifuged again and the double stripped FCS
carefully removed from the pellet. The FCS serum was sterilised
through a 0.22 pm filter units.
The efficiency of the protocol for stripping out oestradiol was
checked by adding a small quantity of [3H] oestradiol before
treating the serum. After stripping, a measure of the activity
remaining in the serum was measured using a scintillation
counter and related to the initial activity before stripping.
97% of the endogenous oestradiol was removed.
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2.10 DNA ANALYSIS BY FLOW CYTOMETRY
(Danova et al., 1990)
Cells were harvested and counted according to protocol
(section 2.1.5). Aliquots containing approximately 106 cells per
tube were collected by centrifuging at 1000 g, 4 oc for 10
minutes. The cells were washed by resuspending pellets in PBS
and then re-centrifuged. The cell pellets were resuspended in 70%
ethanol (v/v) and placed at 4 oc for 30 minutes. Pellets were
collected by centrifuging and then washed once in PBS. 100 pi of
5 mg RNAase /ml of PBS and 100 pi of 100 pg/ml of propidium
iodide dissolved in PBS were added to each pellet and incubated in
the dark for 15 minutes at room temperature. The sample was
analyzed on a Flow Cytometer (FACSCAN; Becton Dickson);
DNA staining was detected at 564 - 607 nm wavelength.
2.11 FILTRATION TECHNIQUES
2.11.1 Concentrating Serum:
Serum was concentrated using different microconcentrators
containing a specific molecular weight cut off filter for
separating proteins of different molecular weights.
A volume of PBS was first spun through the column to remove the
preservatives from the filter. The PBS was discarded and a
sample of serum was placed on top of the filter and centrifuged
in a fixed angle head at 4 OC until the sample volume stopped
reducing.
The centrifugal force depended on the filter being used;
Centricon 10 kDa and 30 kDa filters were centrifuged at 6000 g,
Centricon 100 kDa at 1000 g.
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2.11.2 Gel Filtration:
Sephacryl S-200 was mixed with PBS and poured into a glass
column (10 cm x 7 mm diameter, 11 cm x 18 mm diameter). Three
volumes of PBS were used to wash through the column. A
concentrated sample of serum (section 2.11.1) was then applied
to the top of the column and eluted using PBS. Fractions were
collected every 10 minutes and the presence of protein detected
by measuring the absorbance of a small sample of the fraction
with a spectrophotometer at 280 nm.
2.11.3 Sample and Buffer Preparation for High Pressure
Liquid Chromatography (HPLC):
The buffer was a solution of 8 mM potassium dihydrogen
orthophosphate and 4 mM tetrabutylammonium hydroxide. The
buffer was filtered through 0.2 pm cellulose nitrate filter and
HPLC grade methanol was filtered through 0.45 pm Durapore
filter.
Each sample was centrifuged through a Centricon 10 kDa filter
at 6000 g until all the liquid had passed through the filter. The
filtrate was then used for HPLC analysis (section 2.11.4).
2.11.4 High Pressure Liquid Chromatography (HPLC)
Analysis: (Van Lookeren Campagne et al., 1991)
Analysis of 8-CI cAMP and metabolites was studied using a
reverse-phase pBondapak™ Cis column (3.9 mm internal diameter
x 30 cm) with a particle size of 10 pm. The mobile phase was a
70% : 30% mixture of buffer and methanol with a flow rate of 1.4
ml/minute. Sample was mixed 1:10 (v/v) with mobile phase and a
50 pi volume injected using a WISP autoinjector (Waters
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Associates). Detection of the column elution was monitored at
254 nm using an Absorbance Detector (Waters Associates).
Analysis of the chromatogram and integration of the peaks was
carried out using the MAXIMA computer program (Waters
Associates). Alternatively, the Cis column was attached to a
HP1090 Liquid Chromatography (Hewlett Packard) and samples





3.1 PARTIAL CHARACTERISATION OF THE MCF-7 CELL LINE
3.1.1 Introduction
MCF-7 cells originated from the pleural effusion of a patient
with metastatic breast cancer (Soule et at., 1973). This
established cell line contained oestradiol receptors and on
addition of physiological levels of oestradiol resulted in an
increase in rate of proliferation (Lippman et at., 1976; Lippman,
1980). These cells have been used widely as a model system for
hormone-responsive breast cancer. For example, MCF-7 cells have
been used to study the effects of agents, such as tamoxifen and
retinoic acid, as potential drugs for the treatment of hormone-
responsive breast cancer (Katzenellenbogen et at., 1987;
Sonnenschein et at., 1985; Fontana et at., 1987; Lacroix &
Lippman, 1980).
3.1.2 Hormone-Responsiveness:
MCF-7 cells were obtained direct from the Michigan Cancer
Foundation at passage number 145. These cells were continually
passaged weekly in phenol red DMEM containing 10% FCS (v/v)
(see section 2.1.1). All experiments were carried out using phenol
red free DMEM; phenol red has been identified as having an
oestrogenic effect (Berthois et al., 1986).
Pilot growth experiments were carried out to determine a
suitable concentration of serum required in the culture medium to
demonstrate an oestrogenic response with these MCF-7 cells.
Figure 1(a) shows a representative growth experiment for the
cells cultured in DMEM containing 1% charcoal-stripped FCS (v/v).
Cells were plated with a density of approximately 105 cells per
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well in a 6 well plate and incubated with this medium for
approximately seven days (see section 2.1.4 for protocol). The
population doubling time was determined from the computer
calculated equation based on an exponential line fit for all time
points (Cricket Graph computer program v1.3, Apple Macintosh).
Cells grew with a doubling time of 103 hours ±. 26 (n=6; errors
represent standard deviation).
Figure 1(a) also shows the response of these MCF-7 cells to
exogenous oestradiol (10-8 M). The rate of cellular proliferation
was increased over the basal growth rate (control) by
approximately two fold. This growth stimulation gave a doubling
time of 44 hours ± 2 (n=5); addition of 10-9 M oestradiol gave 45
hours ±_ 2 (n=3). Two concentrations of tamoxifen (0.5 }iM and
1 jiM) added to MCF-7 cells with oestradiol (10-8 M) appeared to
inhibit the rate of proliferation (Figure 1(a)). Furthermore, the
higher concentration of tamoxifen had a greater degree of growth
inhibition. Addition of tamoxifen to MCF-7 cells cultured in the
absence of oestradiol also appeared to inhibite growth, but to a
lesser degree in the presence of oestradiol, and was not
concentration dependent. Addition of retinoic acid (1 p,M) to these
cells showed a similar growth inhibitory effect as for tamoxifen
(Figure 1(b)).
These data demonstrate that for the MCF-7 cells, cultured in
DMEM containing 1% charcoal-stripped FCS (v/v), have a typical
growth response to oestrogen, tamoxifen and retinoic acid as
described in the literature.
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3.1.3 Oestrogen Receptor Content:
The oestrogen receptor content of these MCF-7 cells was
determined from four samples passaged between 147 - 192,
cultured in phenol red DMEM containing 10% FCS (v/v). The
oestrogen receptor assay was kindly performed by Dr R. A.
Hawkins' Laboratory (Department of Surgery , Royal Infirmary,
Edinburgh) using an ER/EIA monoclonal kit (supplied by ABBOTT
Laboratories), which gave an average oestradiol receptor content
of 138 fmol ±. 28 receptor sites / mg soluble protein (n=4; errors
represent standard deviation).
The presence of oestrogen receptors, the growth stimulation
by oestradiol and the growth antagonism by tamoxifen and














The effect of oestradiol (E2), tamoxifen (Tam) and combinations
of oestradiol and tamoxifen (Tam/E2) on growth of MCF-7 cells
cultured in DMEM containing 1% charcoal-stripped FCS (v/v). MCF-
7 cells were plated in 6 well plates and counted according to
sections 2.14 and 2.1.5.
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FIGURE 1(b):
The effect of retinoic acid (RA), oestradiol and combination of
retinoic acid and oestradiol (RA/E2) on growth of MCF-7 cells
cultured in DMEM containing 1% charcoal-stripped FCS (v/v). MCF-
7 cells were plated in 6 well plates and counted according to
sections 2.14 and 2.1.5.
Data are the means of triplicate values + standard deviation of a
representative experiment.
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3.2 THE EFFECT OF 8-CI cAMP ON GROWTH OF MCF-7 CELLS
IN CULTURE
3.2.1 Introduction
The reported concentration of 8-CI cAMP that gives 50%
growth inhibition (IC50) after 5 days in MCF-7 cells is 1pM
(Katsaros et al., 1988). These MCF-7 cells were stimulated by a
two fold increase with oestradiol (10 nM) cultured in medium
containing 6.5% charcoal-stripped FCS (v/v). The authors
demonstrated that this growth stimulation could be inhibited by
8-CI cAMP (10 pM). Furthermore, 67% growth inhibition was also
observed after 3 days by 50 pM 8-CI cAMP with MCF-7 cells
cultured in medium containing 10% unstripped FCS (Katsaros et
al., 1987).
3.2.2 Antiproliferative Effects Of 8-CI cAMP:
MCF-7 cells were set up in 6 well plates according to section
2.1.4 and cultured in DMEM containing 1% charcoal-stripped FCS
(v/v) with oestradiol (10 nM) and 8-CI cAMP (10 pM). Cell
numbers were determined for each plate (section 2.1.5) at time
points indicated on Figure 2.
The oestradiol growth stimulation appeared to be unaffected
by 8-CI cAMP (Figure 2). Moreover, 8-CI cAMP (10 pM) did not
have an effect on the basal growth rate of MCF-7 cells (control).
These data suggest that in these culture conditions MCF-7 cells




The effect of oestradiol (E2), 8-CI cAMP and combination of
oestradiol and 8-CI cAMP (E2/8-CI) on growth of MCF-7 cells
cultured in DMEM containing 1% charcoal-stripped FCS (v/v).
Data are the means of triplicate values + standard deviation of a
representative experiment.
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3.3 THE EFFECT OF SERUM ON INHIBITION OF MCF-7 CELLS
BY 8-CI cAMP WITH MCF-7 CELLS
3.3.1 Introduction:
To determine if the absence of an antiproliferative effect on
MCF-7 cells by 8-CI cAMP (10pM) (see section 3.2) was due to the
low serum concentration and/or charcoal-stripping of serum, MCF-
7 cells were cultured in medium containing different
concentrations of serum.
3.3.2 Serum-Dependent 8-CI cAMP Growth Inhibition:
Growth experiments with MCF-7 cells were set up according to
section 2.1.4 with approximately 105 cells/ well of a six well
plate. Cells were cultured in media containing different
concentrations of charcoal-stripped or unstripped FCS in the
presence or absence of oestradiol (10 nM) and 8-CI cAMP (10 pM).
Figure 3 shows a bar chart with each bar representing the
percentage of treated cell number relative to the control cell
number (i.e. in the absence of drug; 100%) after a 120 hour
incubation. Addition of 8-CI cAMP (10pM) to MCF-7 cells cultured
in DMEM containing 1% unstripped or charcoal-stripped FCS (v/v)
did not appear to have an effect on growth. However, growth
inhibition by 8-CI cAMP was evident with MCF-7 cells cultured in
unstripped or charcoal-stripped 10% FCS (v/v). Furthermore,
growth inhibition was also present with 5% unstripped FCS (v/v),
but the degree of inhibition was less than for 10% FCS (v/v).
Growth stimulation by oestradiol had a more pronounced effect
with MCF-7 cells cultured in lower concentrations of serum;
maximum stimulation with 1% charcoal-stripped FCS (v/v).
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However, the results for growth of MCF-7 cells cultured in
different serum concentrations with oestradiol and 8-CI cAMP
appeared similar for cells in the absence of oestradiol. In other
words, the growth inhibition of MCF-7 cells appeared to be
dependent on the concentration of serum in the medium,
irrespective of the presence of oestradiol.
3.3.3 Non-Antaaonistic Effect of 8-CI cAMP:
The numerical data from Figure 3are presented in Table 1.
Comparison is made between the degree of oestrogenic growth
stimulation of MCF-7 cells cultured in the absence and the
presence of 8-CI cAMP. From these data it appears that 8-CI cAMP
had no effect on the oestrogenic stimulation of MCF-7 cells
cultured with different concentrations of serum. This suggests
that this cAMP analogue does not antagonise the oestrogenic














FIGURE3; Theeffectof8-CIcAMP(10p. ),o stradiolE2;10nanc mbin tionb t(+8-CI)ogrowthMCF-7cellsultured for120h u sinDMEMco taining- A:10%FCS,B5 ,C%,D:charcoal-strippedFCSandE:10ch rcoalstrippedF S(v/v). Cellnumbersieachexp rim ntareexpr ss dp rcentagofthcont olulturwhichn ither8-CIcAMPoestradiolwas added.E chb rrepres ntsthmeaoftle tthrexperiments±stan ardd vi tion.
% FCS (v/v) 10% 5% 1%
1. 8-CI cAMP (10|j.M) 45% 60% 92%
2. Oestrodiol (E2; 10nM) 142% 179% 205%
3. E2 + 8-CI cAMP 81% 148% 201%
4. Fold stimulation in
growth by E2
1.42 1.79 2.05
5. Fold stimulation in
growth by E2 in the
presence of 8-CI cAMP
1.80 2.47 2.18
Table 1:
Effect of oestradiol (E2; 10 nM), 8-CI cAMP (10 jiM), and combination of both
drugs on the growth of MCF-7 cells cultured for 120 hours in different %FCS (v/v)
containing DMEM (data taken from Figure 5, see legend).
Row 1,2 & 3 data are expressed as a percentage of drug treated cell number against
control cell number (absence of drug).
Row 4 gives the ratio of cell number for oestradiol treated cells against control cell
number (fold stimulation by oestradiol).
Row 5 gives the ratio of cell number for cells treated with oestradiol and 8-CI cAMP
against 8-CI cAMP treated cell numbers (fold stimulation by ostradiol in the
presence of 8-CI cAMP).
3.4 EXTRACTION OF PROTEIN FROM CELLS
3.4 Introduction:
p21 is bound to the plasma membrane and can be extracted
with a double detergent buffer containing Nonidet P40 and sodium
deoxycholate (Debortoli et al., 1985, Katsaros et at., 1987,
Tagliaferri et al., 1988). These groups normalised their samples
to a fixed amount of protein and Western blotted with the
monoclonal Y13-259 to detect p21. They scanned the intensity of
p21 staining on X-ray film by densitometry and expressed the
arbitrary units normalised to the amount of protein for each
sample. Using this approach Katsaros et al. (1988) and Tagliaferri
et al. (1988) reported a concomitant decrease in the level of p21
with growth inhibition of MCF-7 cells by 8-CI cAMP.
Before this approach can be adopted to study p21 with the
cells used in this study, it is necessary to demonstrate that
protein can be extracted consistently for different samples.
3.4.2 Protein Content of Different Cells:
MCF-7 pellets containing different amounts of cells were
prepared into lysates (see section 2.3.1) using Buffer 10, the
double detergent buffer used by the above mentioned authors. The
protein concentration for each lysate was determined using the
Bradford Assay (section 2.4).
The original method described by Debortoli et al. (1985)
disrupted cells using fine syringe needles and cleared the lysate
with a 750 g centrifugation. Protein determination of samples
prepared in this way did not produce a consistent concentration
from lysates prepared from pellets containing the same cell
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number. However, use of a sonicator instead of needles, and a 100
000 g centrifugation to clear the lysate of debris, produced a
linear extraction of protein for known cell numbers as shown in
Figure 4. The line through the points does not intersect zero
because of the protein aprotinin, a proteinase inhibitor, added to
Buffer 10. Preparation of lysates from RFHO 206F and RFHO 6N1
cell pellets also produced a similar plot. From the equation of
these lines the total protein per cell was calculated.
Cell Line protein per cell
MCF-7 = 218 pg
RFH06N1 = 98 pg
RFHO208F = 218 pg
Equations of the line were calculated from plots using the Cricket
Graph computer package, such as Figure 4, and used to determine
the protein content per cell. Each value is the average of at least
two plots.
These data demonstrate that a linear relationship exists
between cell number and concentration of extract protein from a
lysate. A fixed amount of protein can therefore be related to a
known number of cells. However, the amount of extractable
protein may differ for other cell lines. This would make




Protein concentration of cell lysate prepared from MCF-7 cells,
determined by the Bradford Assay
Data are the means of duplicates.
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3.5 QUANTITATIVE ANALYSIS OF p21 BY WESTERN
BLOTTING
3.5.1 Introduction:
Western blotting involves the detection of protein using
specific antibodies (Burnette, 1981). Protein is fixed onto a
membrane support, usually transferred from a PAGE gel, which
can then be treated with antibody followed by an appropriate
detection system such as radiolabel or enzymatic probes.
Y13-259 is a rat monoclonal antibody specific for a single
epitope of p21. However, it does not discriminate between the
different ras gene products (Shih et at., 1979; Furth et al., 1987).
A double antibody technique was employed, this involved cross-
linking Y13-259 bound to p21 with an anti-rat IgG. Detection and
subsequent quantification of p21 was accomplished by the
addition of radiolabeled i25|-protein A which has a high affinity
for IgG (Debortoli et al., 1985) (section 2.6). The quantity of p21
fixed to the blot was determined by autoradiography (section 2.8).
Radioactivity exposed to X-ray film activates the local silver
halide crystals in the film. Development of the film results in a
black stain and the intensity of the stain used as an indication of
the amount of radioactivity present (Sambrook et al., 1989).
3.5.2 Quantitative Analysis Of p21:
To determine the relationship between the intensity of the
autoradiographic signal and the quantity of p21, a single lysate
prepared from MCF-7 cells (section 2.3.1) was used to load the
wells of a 12% SDS-PAGE gel (see sections 2.5.1 and 2.5.2) with
decreasing amounts of protein from 120 to 10 pg. The resolved
proteins were transferred from the gel to nitrocellulose
80
membrane (section 2.5.5). The membrane was Western blotted
(section 2.6.1) and exposed to preflashed or unflashed X-ray film
(see section 2.8.1) for a period of 3 hours before developing and
scanning (section 2.8.2).
The staining of p21 by Y13-259 was very specific and produced
very little background staining (Plate 1). Staining for p21 with
20 pg of lysate is just visible to the eye. To allow direct
comparison of the scanning data for the two pieces of X-ray film,
the data for each film was divided by the value for the 100 pg
sample (i.e. 100 pg= 1 arbitrary unit) (Figure 5). A linear
relationship appears to exist for the scanning data with respect
to the concentration of protein present on the blot. The 10 pg
lysate appears to be at the limit of detection by this technique
for p21 detection, since the lines does not intersect the origin.
The linear regression coefficient was improved when the X-ray
film was preflashed before the blot was exposed compared to
unflashed film; 0.975 and 0.923, respectively. These observations
support the data of Laskey and Mills (1975 & 1979). They
described how preflashing X-ray film before exposure to
radioactivity could improve the linear response of the film.
The actual quantity of p21 can not be determined from this
method because the concentration of p21 in the original lysate
was not known. The concentration of p21 could be determined
using a known concentration of pure p21 to calibrate the staining
on X-ray film. Since pure p21 was not available absolute values
could not be determined; however results can be expressed in




Measurement of p21 by Western blotting with anti-p21
monoclonal (Y13-259) of varying protein concentrations of an
MCF-7 cell lysate.
The blot was exposed to preflashed and unflashed X-ray film for 3
hours. Each point represents the autoradiographic signal,
quantified by scanning and divided by the value for 100 jig/ml
(arbitrary unit= 1).




A representative Western blot for p21 with the Y13-259
monoclonal with a serial diluted MCF-7 cell lysate.
An MCF-7 cell lysate (section 2.3.1) was loaded at decreasing
concentrations of protein from 120 to 10 jig (decreasing by 10 jig
per lane).
M- lysate prepared from NIH/3T3 v-ras transformed cells (20 pg
of protein loaded).
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3.6 ALTERNATIVE METHODS OF QUANTIFYING WESTERNS
3.6.1 Introduction:
As demonstrated in section 3.4 the amount of soluble protein
extracted from MCF-7 cells was related to the cell number. This
suggests that loading of protein from different samples of an
individual cell line, a direct comparison of the amount of p21
would be possible. However, this assumes that the extraction of
soluble protein for each sample of cells is consistent. To ensure
that protein content can be related to cell number for each
experiment it would be necessary to construct a standard
calibration plot of protein concentration versus cell number for
each sample (eg. control cells, drug treated cells, etc.). Due to
limited amounts of cellular material during experiments this is
not always possible. Alternatively, an internal standard could be
measured, preferably a protein that is extracted with the same
efficiency as p21. Hypothetically, a number of possibilities do
exist, such as cytoskeletal proteins and chromatin. However, if
these proteins are to be considered as internal standards then
they must be expressed at a constant level in the presence of
different agents. Actin was considered a good candidate since
mRNA analysis of ras oncogene has been studied normalised to
constitutively expressed actin mRNA (Bignami et ai, 1988). Other
alternatives considered were tubulin, cytokeratin and acid
soluble histones.
3.6.2 Actin and Tubulin Proteins:
To detect the level of actin a polyclonal antibody was used,
and for tubulin both a polyclonal and a monoclonal antibody were
used in Western blotting (section 2.6.1). The appropriate IgG,
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raised against the host species, for the primary antibody was
also used. Rainbow™ Protein Molecular Weight Markers (200 -
14.3 kDa) contain proteins of known molecular weights coupled to
dyes with specific colours. These proteins were used to indicate
where the blot could be divided into two parts to give sections of
different molecular weights; one section would contain the 21
kDa proteins and the other part the higher molecular weights of
tubulin (55 kDa) and actin (42 kDa). Each section of the blot was
then incubated with the appropriate antibodies (section 2.6.1).
To confirm that staining with these antibodies could be used
as internal standards for quantifying p21, at least three criteria
must be satisfied:
1. There is a linear relationship with respect to intensity of
signal on X-ray film versus quantity of protein present (see
section 3.5).
2. The ratio of p21 : INTERNAL STANDARD produce a constant
value for varying concentrations of loaded protein on the blot.
3. The amount of protein is unchanged by drug treatment.
To address these issues soluble protein from a single MCF-7
cell lysate (section 2.3.1) was loaded in decreasing amounts of
protein on a 12% SDS-PAGE gel and run (sections 2.5.1 and 2.5.2).
The gel was blotted (section 2.5.5) and cut into two sections; one
section contained proteins less than 30 kDa and the other section
greater than 30 kDa. The higher molecular weight section of the
blot was incubated with tubulin and actin polyclonal antibodies
and the lower section with Y13-259 for p21 (section 2.6.1). The
resulting blot was exposed to preflashed X-ray film (section
2.8.1) and scanned (section 2.8.2).
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Plate 2 shows that the intensity of signal specific for p21
decreased with respect to the decreasing concentration of loaded
protein on the blot (as previously demonstrated in section 3.5).
This, however, was not the case for actin or tubulin staining. The
tubulin signal appeared to increase as the protein concentration
decreased, irrespective of whether or not the antibody was
polyclonal or monoclonal. The actin staining was inconclusive
because the signal was too weak. A linear relationship, as
described for p21, for intensity of signal against the
concentration of protein of an MCF-7 lysate could not be
demonstrated for actin or tubulin.
However, the lysate produced from the NIH/3T3 v-ras
transformed cell line used as a marker for p21 had a strong
staining for tubulin using the monoclonal antibody. Plate 3 shows
a Western blot of decreasing protein concentration of this lysate
for p21 and tubulin. As demonstrated by this result, a
relationship between tubulin staining with respect to protein
concentration does exist. Using the scan data for the tubulin
signal and the p21 signal calculations were made to determine if
a constant ratio existed between the signals. A constant value for
the ratio of p21 : tubulin signal intensity was evident for the
first five protein concentrations but only if the log 10 of the scan
data for p21 and tubulin were taken (Table 2):
=> log-io(tubulin) : Iogi0(p21)
These data demonstrate that tubulin in an NIH/3T3 v-ras cell
lysate could be used to monitor the extraction of p21. However,
this anti-tubulin antibody does not appear to work for the MCF-7
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cell line. A hypothetical explanation for this difference may be
antibody tissue type specificity. Cell type specificity of
antibodies has been observed for the cytoskeletal protein myosin
(Smith et al., 1983). Antibodies raised against myosin from one
cell type can cross-react with myosin from the same cell type of
other species. However, cross-reactivity of the antibody to other
cell types from the original animal is poor.
3.6.3 Cvtokeratin 19:
The monoclonal antibody BA17 stains a cytokeratin species
with a molecular weight of 19 kDa (staining of MCF-7 cytokeratin
19 has been previously demonstrated by Dr Joyce Taylor-
Papadimitriou, Imperial Cancer Research Fund, London; personal
communication). This protein was considered another alternative
as an internal standard for quantifying p21.
MCF-7 cells were plated in 75 cm2 flasks before being treated
for 120 hours with either oestradiol (10 nM), tamoxifen (1 pM) or
retinoic acid (1 pM) (section 2.1.4). Cells were collected and
lysates prepared for each sample (section 2.1.5 and 2.3.1). The
pellets that remained after the 100 000 g centrifugation, during
preparation of lysates, were used for extraction of histone
proteins (section 2.3.2). Each sample was loaded on a 12% SDS-
PAGE gel at two concentrations, 80 pg and 100 pg of soluble
protein (section 2.5.1 and 2.5.2). After transfer of the gel to
nitrocellulose (section 2.5.5), the blot was sectioned, and the
high molecular weight section incubated with actin and tubulin
polyclonal antibodies and the other section incubated with
antibody for p21 and cytokeratin 19 (section 2.6.1).
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Plate 4 shows that staining with BA17 antibody of control
lysates (incubated in the absence of drug) produced a very faint
stain of at least two bands; one with an approximate molecular
weight of 19 kDa and the other approximately 13 kDa.
Interestingly, addition of tamoxifen to MCF-7 cells resulted in
the appearance of three bands, two of which corresponded to
those of the control but with a more intense stain. Retinoic acid
treatment also resulted in staining of two bands corresponding to
the control bands, an as with tamoxifen, the signal was more
intense. Oestradiol treatment of MCF-7 cells did not increase the
signal intensity of these proteins and the staining pattern
resembled the control.
It is not known if these bands are all related to cytokeratin 19
or if they are proteins with the same epitope detected by BA17.
Nevertheless, these data suggest that tamoxifen and retinoic acid
treatment of MCF-7 cells alters the expression of different BA17
detectable proteins compared to untreated cells. The observation
that drug treatment can preferentially alter expression of BA17
detectable proteins makes this antibody unsuitable for staining
an internal standard for p21 extraction.
3.6.4 HISTONES:
Histones are acid soluble proteins that bind to genomic DNA to
form chromatin. These proteins are not soluble in Buffer 10 with
the result that they are pelleted during the 100 000 g
centrifugation. These proteins were extracted from the pellet as
described in section 2.3.2.
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Histone extracts prepared from the sample pellets from the
above experiment (section 3.6.3) were loaded and run through a
12% SDS-PAGE gel (section 2.5.1 & 2.5.2). Samples of
commercially prepared histone extracts were also prepared as
detailed for the histone extraction from pellets (section 2.3.2)
and resolved by SDS-PAGE gel. The gel was stained according to
the method for Coomassie blue staining (section 2.5.4). The
stained gel, shown by Plate 5, shows that the majority of the
proteins extracted from the pellet had similar mobilities on SDS-
PAGE gel as the major protein species in the commercial
preparations of histones. The Coomassie stained gels were
scanned in the same way the X-rays were scanned (section 2.8.2).
No relationship was found between histone staining and p21. It
is possible that extraction of histone from the pellets may not be
consistent.
3.6.5 Protein:
Hypothetically, it would be more advantageous to measure a
protein of interest in an extract by normalising the result to an
internal standard. For example, RNA measurements (Northern
Analysis) are usually not normalised to quantity of loaded RNA
because of possible degradation of the sample but normalised to,
for example, actin mRNA that should degrade at the same rate as
the RNA of interest, therefore giving an internal standard for
detectable RNA. The Bradford Assay (Bradford, 1976) is based on
the observation that the absorbance of Coomassie brilliant blue G-
250 shifts from 465 nm to 595 nm when it binds to protein. The
concentration of protein is determined from the absorbance of G-
250 bound to protein at 595 nm. For example, determination of a
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protein concentration (10 mg/ml) by the Bradford assay for
solutions each containing a single protein of different molecular
weights, including thyroglobulin, catalase or lysozyme would
yield similar results of approximately 10 mg/ml (Bio-Rad Protein
Assay handbook, p.4; BIO-RAD Laboratories). In other words, if a
lysate with 1 mg/ml of soluble protein on analysis then partially
degraded, it could still give the same result when measured again
giving no indication of degradation. This suggests that if two
identical samples had a fixed amount of protein loaded on a gel,
the quantity of protein resolved may not be the same if one of
those samples had partially degraded, possibly affecting the
staining of a specific protein.
To guard against this gels could be Coomassie stained and the
staining intensity of each sample compared. However, transfer of
stained proteins to nitrocellulose is impaired (Stott, 1989).
Naphthol blue black can stain protein bound to nitrocellulose. This
can then be visually checked for differences in protein staining
per sample. However, differences of 10 pg per sample are
difficult to see.
Attempts to normalise the p21 signal with actin, tubulin,
cytokeratin 19 and histone did not prove to be successful for this
particular study. It was therefore decided that p21 data would be
normalised to the amount of loaded protein. To reduce the level of
protein degradation, lysates were prepared at 4 oc and freezing
and thawing kept to a minimum. In addition, blots were stained
for total protein using naphthol blue black (section 2.6.3) to




Plate2: ArepresentativeW st rnbloofaMCF-7c lllysa elo dedwi hde r asingoncentr ionp t i andimmunoblottedfortubulin(T),ctA)p21. M-NIH/3T3M rastransfo medcelllysat
Plate 3:
A representative Western blot of an NIH/3T3 v-ras cell lysate
loaded with decreasing concentrations of protein and
immunoblotted for p21, phosphorylated p21 (pp21) and tubulin
(T).
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Protein (jxg/ml) 50 37.5 28.1 21.1 15.8 11.9 8.9 6.7





















0.80 0.80 0.79 0.80 0.77 0.50 0.40 0.50
4. log Tubulin/
log p21 cellular
0.85 0.80 0.72 0.72 0.64 0.40 0.33 0.38
TABLE 2:
Scan data produced from a Western blot of a lysate of NIH/3T3 v-
ras transfected cells loaded at different protein concentrations
and immunoblotted for p21 and tubulin.
Scan data derived from plate 3
1. Signal intensity for tubulin stained with the mouse
monoclonal.
2. Signal intensity for phosphorylated viral p21 and cellular p21
stained with Y13-259 monoclonal.
3. Ratio of logio(tubulin) : log 1 o(viral p21)
4. Ratio of logio(tubulin) : logi0(cellular p21)
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A representative Western blot of MCF-7 cells, treated with drug
for 120 hours before being prepared as a lysate, immunoblotted
for tubulin (T), actin (A), p21 and cytokeratin 19 (C19).
MCF-7 cells were culture for 120 hours either in the absence
(control; C) or the presence of oestradiol (10 nM; E), tamoxifen
(1 piM; T) or retinoic acid (1jiM; R).
Two sets of concentrations were loaded for each sample; 80 pig
and 100 pg.







Plate5: ACoomassiebluestained12%SDS-PAGEgelofcomm rcialhist npreparati nsandcisolu le extractsfromMCF-7c lllysatepelle s. Hn,iiiandvwereload dt10pgerlan .S mplest4werpreparefrothlys tepell tsof MCF-7extractsusedinsection3.6.3(photograph4)a dlo d t50elan .
3.7 EFFECT OF 8-CI cAMP ON THE EXPRESSION LEVEL OF
p 2 1
To establish if the growth inhibitory response by 8-CI cAMP in
DMEM containing 10% FCS (v/v) was associated with a change in
p21 expression levels, MCF-7 cells were plated in 175 cm2 flasks
and treated with oestradiol (10 nM), 8-CI cAMP (10 pM) or
oestradiol and 8-CI cAMP for 120 hours (section 2.1.4). After this
period cells were collected from the flasks (section 2.1.5) and
prepared into lysates (section 2.3.1). A fixed quantity of soluble
protein (100pg and 50pg), as determined by the Bradford assay
(section 2.4), was loaded for each sample on to a 12% SDS-PAGE
gel and resolved (sections 2.5.1 & 2.5.2). Western blotting was
performed for p21 according to section 2.6.1. The blot was then
exposed to X-ray film (section 2.8.1) and the signal quantified by
scanning (section 2.8.2). After developing, the blots were finally
stained with naphthol blue black (section 2.6.3) to check that the
general staining intensity for protein in each lane appeared
similar.
Plate 6 shows a representative blot for this experiment. The
staining for p21 was very specific with virtually no visible
background staining. The intensity of the signals also appeared
very similar with the naked eye. Table 3 contains the
accumulative scanning data from all the experiments; the scan
data is presented as a percentage of the control data (i.e. 100%).
The p21 expression in MCF-7 cells after culture in DMEM
containing 10% FCS (v/v) did not appear to be affected by 8-CI
cAMP even though the cells were growth inhibited after the five
day exposure. Treatment with oestradiol produced a very small
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increase in expression level of p21 by 1.3 fold over the control.
However, this increase was possibly not significant due to a high
value of 38.6% for the standard deviation. Experiments in which
MCF-7 cells were cultured with DMEM containing 1% FCS (v/v)
produced similar results as for 10% FCS conditions (data not
shown).
Tagliaferri et al. (1988) and Katsaros et at. (1988) studied the
effects of 8-CI cAMP on expression of p21 after three days. This
time period was also investigated with MCF-7 cells in DMEM
containing 10% FCS (v/v) with 8-CI cAMP (10pM), and again
produced a similar result as for the five day exposure (data not
shown).
These MCF-7 cells treated with 8-CI cAMP (10pM) did not
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Plate 6:
A representative Western Blot of lysates, prepared from MCF-7
cells treated with drug for 120 hours and immunoblotted for p21.
C- control, no drug; E- oestradiol (10 nM); 8- 8-CI cAMP (10 pM);
E8- oestradiol and 8-CI cAMP
Each sample was loaded at two concentrations; 100 pg and 50 pg
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DRUG % of CONTROL SIGNAL
Oestradiol (10 nM) 130% ± 38.6
Oestradiol (10 nm) =
+ 8-CI cAMP (10 |iM)
101% ± 31.0
8-CI cAMP (10 jiM) = 100% ± 30.0
Table 3:
The expression level of p21 in MCF-7 cells exposed to drug for
120 hours.
The above data represents the average of seven experiments
presented as a percentage of the control signal (i.e. 100%).
Errors are presented as standard deviations.
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3.8 THE EFFECT OF 8-CI cAMP ON THE EXPRESSION LEVELS
OF THE cAMP-DEPENDENT PROTEIN KINASE REGULATORY
SUBUNITS
Katsaros et at. (1988) correlated a change in the relative
expression levels of the cAMP-dependent kinase regulatory
subunits Rl and Rll with the growth inhibition of MCF-7 cells
treated with 8-CI cAMP, in the presence or absence of oestradiol.
To determine whether 8-CI cAMP (10 pM) could mediate a change
in Rl and Rll expression MCF-7 cells were treated with drug in
DMEM containing 10% FCS (v/v) containing medium for 72 hours.
Cells were collected after incubation and prepared in to cytosols
(section 2.3.3). Two volumes of each cytosol were treated with
[32P] 8-azidoadenosine-3':5' cyclic monophosphate according to
section 2.7 before being loaded (section 2.5.1) onto a 12% SDS-
PAGE gel (section 2.5.2). The gel was dried (section 2.5.3) and
exposed to X-ray film (section 2.8.1). The X-ray film was
developed and the intensity of signal on the film measured by
scanning (section 2.8.2).
The photoaffinity labelling of Rl (49 kDa) and Rll (55 kDa),
shown in plate 7, was very specific with very little visual
background. Each sample was loaded at two volumes; 75 pi and 25
pi. Table 4 shows the scan data expressed as a ratio for Rl : Rll.
The oestradiol treated cells appeared to have a lower value for
the Rl : Rll ratio which would indicate an increase in expression
of Rll, or a decrease in Rl. Moreover, no apparent change in the
expression ratio of the regulatory subunits was evident for cells
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The expression ratio of the Rl and Rll cAMP-dependent protein
kinase regulatory subunits in MCF-7 cells treat with drug for 72
hours.
The above data represents the value for the ratio of Rl : Rll from
the scanning data derived from plate 7. The two sets of data are
for the same sample but different volumes were used for the
assay.
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3.9 CELL CYCLE ANALYSIS OF MCF-7 CELLS TREATED WITH
8-CI cAMP
3.9.1 Introduction:
Tagliaferri et al. (1988) studied the effect of 8-CI cAMP
(10 |iM) on the cell cycle progression of MCF-7 cells cultured in
10% FCS conditions for three days. The authors showed that the
inhibition of cell proliferation in the presence of 8-CI cAMP did
not correspond to any difference in cell cycle progression
compared to untreated cells. This experiment was repeated using
our MCF-7 cells to confirm if the growth inhibition observed with
these cells by 8-CI cAMP had an effect on cell cycle progression.
3.9.2 Cell Cvcle Progression:
MCF-7 cells were cultured in 175 cm2 flasks until the cells
appeared to occupy 50% of the flask surface. The medium was
replaced with DMEM containing 10% FCS (v/v) or HITS (section
2.2.1); a serum substitute (see section 3.11). 24 hours later,
medium was replaced with fresh medium (control) or fresh
medium with 8-CI cAMP (10 |iM). After 72 hours the cells were
harvested (section 2.5.1). The cell suspension was centrifuged at
750 g for 10 minutes at 4 oc to collect the cell pellets and then
treated for flow cytometry analysis (section 2.10). Cells were
analyzed using a FACScan flow cytometer (Becton Dickinson)
and determination of the intensity of fluorescence of DNA bound
propidium iodide dye versus cell number was calculated and peak
areas determined. Three samples of 106 cells per ml from each
flask were analyzed and the average for each stage of the cell
cycle determined.
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The FACscan data in Table 5, shows that 8-CI cAMP causes an
accumulation of MCF-7 cells in the G2 + M cultured in DMEM
containing 10% FCS (v/v). However, drug in HITS medium appears
to have no effect on the cell cycle. The data is expressed as
percentage of the control and plotted in Figure 6.
These data suggest that the growth inhibition of MCF-7 cells
cultured in medium containing 10% FCS (v/v) may be associated
with a blockage in G2 + M phase; this contradicts previous
reports. No blockage by 8-CI cAMP with MCF-7 cells cultured in
HITS medium is consistent with the findings from section 3.11.3,
that 8-CI cAMP has no effect on proliferation in these conditions.
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Phase GO + G1 S Phase G2 + M
HITS 74.2 ± 0.9 18.4 ± 0.7 7.4 ± 0.8
HITS-8-CI 75.8 ± 1.6 17.3 ± 3.5 7.0 ±1.8
% of control 102% 94% 95%
10% 70.4 ± 1.5 26.0 ± 2.0 3.6 ± 0.7
1 0%-8-CI 67.4 + 1.4 19.9 ± 2.0 12.8 ± 0.8
% of control 96% 77% 356%
Table 5:
The effect of 8-CI cAMP on the Cell cycle progression of MCF-7
cells incubated in DMEM containing either 10% FCS (v/v) or HITS
for 72 hours in the absence (control) or presence of drug (10 pM).






















The effect of 8-CI cAMP (10 pM) on the cell cycle progression of
MCF-7 cells cultured for 72 hours in DMEM containing 10% FCS
(v/v) or HITS.
Each bar is expressed as a percentage of the cell cycle phase
relative to the control cells (no drug; 100%); values derived from
Table 5.
Data are means of triplicate values ± standard deviation.
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3.10 SERUM-DEPENDENT 8-CI cAMP INHIBITION OF MCF-7
CELLS
The only observation so far made with MCF-7 cells in this
study with regards to 8-CI cAMP (10 pM) is growth inhibition.
However, this response appears to be serum-dependent (section
3.3). To clarify the response, media containing a range of FCS
concentrations were added to MCF-7 cells plated in 6 well plates
(section 2.1.4) in the presence or absence (control) of 8-CI cAMP
(10 pM). All plates were counted after a period of 120 hours
(section 2.1.5).
Data presented in Figure 7 show that the control cell numbers
increased slowly from 1% to 6% FCS (v/v). The arrow on the
Figure indicates the number of cells present per well before
addition of media. This would suggest that the lower
concentrations of serum in the media do not produce similar basal
growth levels. However, growth inhibition by 8-CI cAMP appears
to be less with 1% than for any other concentration of serum.
Furthermore, the level of growth inhibition increased with 2%
serum and a further, but smaller level in inhibition occurred with
3% - 5%. By 5% the level of growth inhibition plateaus, giving no
further increase with increasing concentration of serum.
These data suggest that the serum-dependent growth




The effect of 8-CI cAMP (10 pM) on growth of MCF-7 cells
cultured for 120 hours in DMEM containing different
concentrations of FCS (v/v).
Arrow indicates cell number on addition of drug.
Data are the means of triplicate values + standard deviation of a
representative experiment.
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3.11 USE OF SERUM-FREE MEDIUM TO STUDY THE
INVOLVEMENT OF A PUTATIVE SERUM FACTOR
DEPENDENT 8-CI cAMP INHIBITION
3.11.1 Introduction:
To investigate this putative serum borne factor(s) as
suggested by data from section 3.3 and 3.10 it would be
advantageous to develop culture conditions that do not require the
addition of serum to medium in order to maintain cellular
proliferation. If the thesis is correct, in serum-free conditions
MCF-7 cells would not respond to 8-CI cAMP unless the factor(s)
was added to the medium. Such a bio-system will enable the
identification of potential factors.
MCF-7 cells have been successfully cultured in serum-free
conditions containing EGF, insulin, transferrin and prostaglandins
(Barnes & Sato, 1979). However, due to the expense of EGF and
prostaglandin (PGF2«) this precluded the use of this serum-free
medium. Hydrocortisone, insulin, transferrin, oestradiol and
selenium (HITES) have been used in medium as a serum substitute
for the growth of small cell lung carcinoma cell lines
(Carney et al., 1981). Furthermore, HITS has also been used
successfully as a serum substitute for the growth of ovarian
cancer cell lines including PE01 and PE014 (Personal
communication with Simon Langdon, Imperial Cancer Research
Fund, Edinburgh).
3.11.2 Serum-Deoendent Inhibition Of PEQ1 Cells Bv 8-CI
cAMP:
Inhibitory effects of 8-CI cAMP on the ovarian cancer line
PE01 have not been reported. Since these cells can grow in serum-
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free conditions a repeat of the previously described experiment
(section 3.10) was set up using RPMI 1640 medium containing
HITS and different concentrations of FCS. Cells were treated with
or without (control) 8-CI cAMP (10pM) for 120 hours before
determining cell numbers.
Figure 8 shows that the control PE01 cell number increased
from a plating density of 105 cells/well to approximately 3 x 105
cells/well cultured in HITS medium only. This indicates that a
basal growth level for these cells was present for HITS medium.
Furthermore, these cells did not appear to respond to 8-CI cAMP.
However, 8-CI cAMP was inhibitory to proliferation of PE01 cells
in the presence of FCS. A similar response as described above for
MCF-7 cells applied; the level of inhibition increased with serum
content, plateauing off by 3% serum.
These data demonstrate that PE01 cells have a similar serum-
dependent growth inhibition by 8-CI cAMP as described for the
MCF-7 cells.
3.11.3 Effect Of 8-CI cAMP On MCF-7 Cells Cultured In
Medium Containing HITS:
To determine if HITS could be used as a serum substitute for
MCF-7 cells, and if addition of 8-CI cAMP (10 pM) had an effect
on proliferation in these conditions, a full growth experiment
was set up to study the effect of DMEM containing HITS in the
presence or absence (control) of 8-CI cAMP plus or minus
oestradiol (see section 3.1 for description of set up).
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Control MCF-7 cells (no drug) appeared to proliferate with a
doubling time of 2 days (Figure 9(a)). This doubling time was
equivalent to the time for MCF-7 cells cultured in DMEM
containing 1% charcoal-stripped FCS (v/v) in the presence of
oestradiol (10-s M) (section 3.1). These cells cultured in HITS
medium do not appear to be stimulated by oestradiol.
Furthermore, 8-CI cAMP (10 pM) does not appear to affect growth.
These data demonstrate that the serum-free HITS medium is
suitable for maintaining proliferation of MCF-7 cells during
culture for approximately 7 days. This proliferation is also
unaffected by 8-CI cAMP due to the absence of serum.
3.11.4 Effect of 8-CI cAMP On The Growth Of MCF-7 Cells
Cultured In HITS Medium Containing FCS:
To confirm that the serum-dependent 8-CI cAMP inhibition of
MCF-7 cells can still be demonstrated in DMEM containing HITS
(HITS medium) a repeat of the PE01 experiment described in
section 3.11.2 was repeated.
Again, 8-CI cAMP appeared to unaffect the proliferation of MCF-
7 cells cultured in HITS medium in the absence of serum (Figure
9(b)). This result appears similar to the data presented in section
3.10 (Figure 7); the basal growth rate (control) increased with
the concentration of serum. Furthermore, the level of 8-CI cAMP
growth inhibition increased with the concentration of serum,
plateauing off by 3% serum.
These data demonstrate that the presence of HITS in the
medium did not affect the serum-dependent 8-CI cAMP growth
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inhibition of MCF-7 cells. Furthermore, HITS medium in the
presence of 8-CI cAMP (10 pM) had no inhibitory affect on cellular
proliferation.
3.11.5 Advantage Of HITS In Medium:
To study the effect of an antiproliferative drug like 8-CI
cAMP, the drug needs to be added to viable, proliferating cells. If
control cells do not proliferate in the culture conditions then
addition of an antiproliferating agent would appear to have no
effect. Addition of HITS to culture medium, therefore, maintains
a level of proliferation in PE01 cells and MCF-7 cells which
enables one to make the conclusion from the above data that
8-CI cAMP has no growth inhibitory affect on cells cultured in the
absence of serum. Because a basal growth level can be maintained
in HITS medium in the absence of serum, data from the above
experiment (section 3.11.3) can now be expressed as a percentage
of control growth (Figure 9(c)); each bar is represented as a
percentage of cell numbers drug treated with respect to control
cell numbers (no drug; 100%).
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FIGURE 8:
The effect of 8-CI cAMP (10 pM) on the growth of PE01 cells
cultured for 120 hours in RPMI containing HITS and different
concentrations of FCS (v/v).
Arrow indicates cell number on addition of drug.










The effect of oestradiol (E2;10 nM), 8-CI cAMP (8-CI; 10 p.M) and
combination of oestradiol and 8-CI cAMP (E2/8-CI) on growth of
MCF-7 cells cultured in DMEM containing HITS (sections 2.14,
2.1.5 and 2.2.1).
Data are the means of triplicate values + standard deviation of a
representative experiment
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%FCS in HITS Medium
Figure 9(b):
The effect of 8-CI cAMP (10 pM) on the growth of MCF-7 cells
treated for 120 hours in DMEM containing HITS and different
concentrations of FCS (v/v).
Arrow indicates cell number on addition of drug.




The effect of 8-CI cAMP (10pM) on the growth of MCF-7 cells
treated for 120 hours in DMEM containing HITS and different
concentrations of FCS (v/v).
Data are expressed as a percentage of control cells (not treated
with drug) of triplicates ± standard deviation.
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3.12 OTHER CELL LINES HAVE A SERUM DEPENDENCE FOR
8-CI CAMP INHIBITION
To determine if the serum-dependent 8-CI cAMP growth
inhibition demonstrated in MCF-7 and PE01 cells extended to
other cell lines the following were screened: human ovarian
carcinoma cell line PE04, hormone-unresponsive human breast
cancer MDA-MB-231 and the colorectal carcinoma line HT-29.
Cell lines were set up according to the experiment described in
sections 3.11.4 and 3.11.2; cell lines were plated at 105 cells per
well, except HT-29 which was plated at 104 cell/well. The cells
were incubated with the appropriate HITS medium (MCF-7, MDA
and HT-29 cultured with DMEM; PE01 and PE04 cultured with RPMI
1640) plus or minus (control) 8-CI cAMP (10pM) and HITS medium
containing 10% FCS (v/v) plus or minus (control) 8-CI cAMP (10
jj.M) for 120 hours before counting cells (section 2.1.5).
Data in Figure 10 is presented as a percentage of cell number
for wells with 8-CI cAMP against the control numbers (no drug).
All cell lines cultured in HITS medium for 120 hours had an
increase in cell number above the number of cells per well at
time of drug addition. This indicated that for these cell lines,
HITS medium maintained a level of proliferation for the period of
incubation. No appreciable change in cell number was observed on
addition of 8-CI cAMP with any of the cell lines cultured in HITS
medium. However, in the presence of 10% serum there was growth
inhibition. The level of growth inhibition for 10 pM 8-CI cAMP
varied for the different cell lines. PE04, PE01 and MCF-7 were
inhibited the most followed by MDA-MB-231 cells and then HT-29
cells.
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These data suggest that for these cell lines the presence





The effect of 8-CI cAMP (10 pM) on the growth of different cell
lines cultured for 120 hours in medium containing 10% FCS (v/v)
(10% FCS/HITS) or HITS.
Cell numbers are expressed as a percentage of control cells (i.e.
no drug; 100%) of triplicates ± standard deviation.
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3.13 THYMIDINE UPTAKE ASSAY
The experiments studied in the previous section utilize an
assay involving a five day incubation in 6 well plates. Cell number
was determined by harvesting each well and counting the cells
with a Coulter counter. This is a very time consuming process and
therefore limits the number of samples that can be processed. To
enable faster assay and to increase the number of samples
handled a 96 well plate assay was developed using MCF-7 cells. A
repeat of the experiment described in section 3.11.3 was set up
but using the level of [methyl-3H] thymidine incorporated into
cellular DNA as a measure of cellular proliferation (section
2.1.6).
The CPM for 8-CI cAMP (10 pM) treated cells is expressed as
percentage of the control (no drug) in Figure 11. Comparison of
Figure 9(c) and Figure 11 show that MCF-7 cells grown in HITS
medium with drug and different FCS concentrations for a total
time of 78 hours (72 hours with drug plus 6 hours incubation with
[methyl-3H] thymidine) gave similar results by incorporation of
[methyl-3H] thymidine as for cell counting; the level of thymidine
incorporation decreased (i.e. level of inhibition of incorporation
increased). Furthermore, no apparent change in incorporation was




%FCS (v/v) in HITS/Medium
FIGURE 11:
The effect of 8-CI cAMP (10 pM) on the incorporation of [methyl-
3H] thymidine by MCF-7 cells cultured for 78 hours in DMEM
containing HITS and different concentrations of FCS (v/v).
Control MCF-7 cells were cultured in the absence of 8-CI cAMP
(100% incorporation).
Data are expressed as a percentage ±_ standard deviation of
quadruplicates, relative to incorporation by control.
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3.14 CONCENTRATION DEPENDENCE OF THE RESPONSE TO
8-CI cAMP AND 8-Br cAMP
Using the thymidine uptake assay (section 2.1.6) the effect of
different concentrations of 8-CI cAMP and 8-Br cAMP on the
growth inhibition of MCF-7 cells was determined. MCF-7 cells
were incubated in the absence (control) or presence of a
concentration range of 8-CI cAMP (0.5 - 10 pM) or 8-Br cAMP (30 -
360 pM) for 72 hours, cultured in HITS medium or HITS medium
containing 10% FCS (v/v). After incubation, the level of [methyl-
3H] thymidine uptake was measured (section 2.1.6).
MCF-7 cells cultured in HITS medium did not appear to have
thymidine incorporation affected by 8-Br cAMP (Figure 13).
However, 8-Br cAMP did inhibit the incorporation of thymidine by
MCF-7 cells, but like 8-CI cAMP appeared to be dependent on the
presence of serum. The level of inhibition increased with
concentration of 8-Br cAMP and plateaued off by 250 pM.
Concentrations of less than 6 pM 8-CI cAMP did not appear to
affect thymidine incorporation by MCF-7 cells cultured in HITS
medium containing 10% FCS (v/v) (Figure 12).
8-Br cAMP is less potent at affecting proliferation compared
to 8-CI cAMP. An estimated IC50 derived from these plots are
5.5 pM for 8-CI cAMP and 50 pM for 8-Br cAMP. This compares
with the reported values of 1 pM and 57 pM for a five day





The effect of different concentrations of 8-CI cAMP on the
incorporation of [methyl-3H] thymidine in MCF-7 cells cultured
for 78 hours in HITS medium containing 10% FCS (v/v).
Control cells were cultured in the absence of drug (100%
incorporation).
Data are expressed as a percentage ± standard deviation of




The effect of different concentrations of 8-Br cAMP on the
incorporation of [methyl-3H] thymidine in MCF-7 cells cultured
for 78 hours in HITS medium (HITS) or HITS medium containing
10% FCS (v/v) (HITS/10%).
Control cells were cultured in the absence of drug (100%
incorporation).
Data are expressed as a percentage ± standard deviation of
quadruplicates, relative to incorporation by control.
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3.15 HEAT INACTIVATION OF THE SERUM-DEPENDENT 8-CI
cAMP INHIBITORY RESPONSE
3.15.1 Heat Lability Of A Putative Serum Factor MF-sl:
To determine the nature of the factor(s) (IF-s) responsible for
this serum-dependent 8-CI cAMP response, aliquots of FCS were
heated for varying periods of time and at different temperatures.
FCS (500 pi) was heated to 97 OC using a microfuge tube heating
block for a period of 1, 3, 10 or 30 minutes then cooled on ice.
This serum was added to HITS medium to give a 10% (v/v)
solution and assayed for 8-CI cAMP dependent growth inhibition
with by thymidine uptake (section 2.1.6). The control for this
experiment was media added to cells without the addition of drug.
The result shown in Figure 14 demonstrate that FCS heat
treated for 1 minute at 97 oc still retained the same level of
activity as FCS not heat treated. However, FCS heated for 3
minutes or more did not retain IF-s activity.
3.15.2 Temperature Of Heat Inactivation:
To determine the temperature at which IF-s was heat
inactivated, FCS (500 pi) was heat treated for 15 minutes at
different temperatures ranging from 60 °C to 95 °C with 5 °C
increments. The serum was then assayed as described in section
3.15.1.
All growth inhibition (IF-s activity) was lost at these
temperatures except with the untreated FCS (data not shown).
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FIGURE 14:
The effect of 8-CI cAMP (10|iM) on the incorporation of [methyl-
3H] thymidine by MCF-7 cells cultured for 78 hours in HITS
medium containing 10% FCS (v/v) heat treated at 97 °C for
varying periods of time.
Control MCF-7 cells were cultured in the absence of drug (100%
incorporation).
Data are expressed as a percentage ± standard deviation of
quadruplicates, relative to incorporation by control.
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3.16 MOLECULAR WEIGHT ESTIMATION OF IF-s USING
MOLECULAR WEIGHT CUT OFF FILTERS
3.16.1 Introduction:
To isolate IF-s from serum and determine a rough estimation
of its molecular weight, a range of Centricon™ filters were
utilised to produce fractions containing different molecular
weights. Centricon™ filters are composed of specialised
membrane with pore sizes that allow passage of certain
molecular weight species. These filters are supplied in a range of
molecular weight cut offs including 10 kDa, 30 kDa and 100 kDa.
3.16.2 Molecular Weight Estimation Of IF-s:
A sample of FCS (2 ml) was applied to the top of the filters
and centrifuged at 4 oc (see section 2.11.1 for centrifugal force
for the different filters). Molecular weight species too large to
pass through the membrane concentrate above the filter while
the smaller molecules and water pass through the filter
(filtrate). The fractionation was completed when the volume of
the concentrate did not reduce further. Both fractions were
collected and the volume of the concentrate was adjusted to the
original volume applied to the column with PBS. The two
fractions were then added individually and in combination to HITS
medium to give a concentration of 10% (v/v). The media was then
filter sterilised with 0.22 pm filter units before being measured
for IF-s activity with the thymidine uptake assay (section 2.1.6).
A volume of the original serum applied to the filters was retained
and filter sterilised to be used for a positive IF-s activity
control. In addition, a volume of the fractions were run on non-
denaturing 7.5% PAGE gels to check the protein molecular weight
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of each fraction.
Figure 15 shows the data for FCS fractionated using the 100
kDa filter. The concentrate (fraction retained above the filter)
contained the same level of IF-s activity as for unfiltered FCS.
FCS fractionated with the 10 kDa and 30 kDa filters produced a
similar result; the concentrate retained IF-s activity (data not
shown). The filtrate did not appear to retain any activity in the
presence of 8-CI cAMP (10 pM).
These data suggest that IF-s has a rough molecular weight of
greater than 100 kDa. However, it is not possibly to conclude this
since the Coomassie blue stained PAGE gel (plate 8) of the
fractions from the 100 kDa unit suggest the fidelity of the cut
off filter was very poor. The concentrate appears to contain a
high concentration of a 67 kDa protein compared to the filtrate.
Nevertheless, these filters do provide a very convenient method
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10% Filter Fraction (v/v) in Medium Containing HITS
FIGURE 15:
The effect of 8-CI cAMP (10pM) on the incorporation of [methyl-
3H] thymidine in MCF-7 cells cultured for 78 hours in HITS
medium containing 10% (v/v) FCS fraction from a 100 kDa
Centricon filter.
Control MCF-7 cells were not treated with drug (100%
incorporation).
>100K : concentrate; did not pass through filter.
<100K : filtrate; passed through filter.
<>100K: both concentrate and filtrate added at 10% (v/v) each.
Data are expressed as a percentage ±_ standard deviation of
quadruplicates, relative to incorporation by control.
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Plate8: Coomassiebluestain dn n-denaturing7.5%PAGEgelffoetc lfs r mfilte dwi ha100 Centiconfilter. S-FCS;Cconcentrate;-filtrate;Mmarkepr teins. Eachlanewasloadedith10pi.
3.17 GEL FILTRATION CHROMATOGRAPHY OF
CONCENTRATED FCS
3.17.1 Introduction:
Small micron sized beads composed of cross-linked
polysaccharide or polyacrylamide can be used to separate a
mixture of proteins; this technique is known as gel filtration
chromatography. These beads have a fine mesh that allows the
movement of small proteins through them and larger proteins
have a greater resistance to enter these spaces. Proteins can be
separated based on this principle with the larger proteins being
eluted from a column composed of these beads first followed by
the smaller molecular weight species.
3.17.2 10 cm x 7 mm Column:
A volume of FCS was concentrated to a fifth of its original
volume using a 10 kDa Centricon filter (section 2.11.1). The
concentrate (2 ml) was applied to an S-200 sephacryl column (10
cm x 7 mm diameter), pre-equilibrated with PBS, and 750 pi
fractions collected from the column (section 2.11.2). A total of
twenty fractions were collected. Protein concentration for each
eluted fraction was estimated by spectrophotometric absorbance
at 280 nm. Each fraction was added to HITS medium to give a
concentration of 10% (v/v) and filter sterilised (0.22 pm units)
before being assayed with MCF-7 cells for IF-s activity by
thymidine uptake (section 2.1.6). A volume of the fractions were
resolved with a 7.5% SDS-PAGE gel to visualise to proteins
(Plate 9).
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Figure 16 displays the protein concentration of fraction and
the inhibitory activity by 8-CI cAMP (10 pM). Fractions 10 and 11
contain the highest protein concentration and is probably due to
serum albumin (approximate molecular weight of 67 kDa), since it
is the most abundant protein in serum. The majority of the
8-CI cAMP growth inhibition coincided with fractions 6 and 7, and
then diminished to give no activity by fraction 13.
These fractions probably contain the majority of the unknown
factor IF-s. Plate 9 shows that fraction 6 and 7 does not have as
much of the 67 kDa protein as the later fractions, suggesting that
IF-s is not albumin.
3.17.3 11 cm x 18 mm Column:
A second S-200 sephacryl column with a larger volume (11 cm
x 18 mm diameter) was run to allow a larger volume of
concentrate (3 ml) to be fractionated. A total of forty, 1.5 ml
fractions were collected and protein concentration and IF-s
activity measured as described for section 3.17.2.
This column gave a more detailed protein profile for FCS
(Figure 17) compared to the smaller volume column. The majority
of the 8-CI cAMP growth inhibitory effect was contained in
fractions 10, 11 and 12. Again, the majority of the activity was
eluted before the major protein peak.
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Criticism of Gel Filtration Chromatography Experiments
(section 3.17):
Ideally, a sample volume of 0.5 - 5 % of the column bed
volume should be applied for good resolution of sample
components (Gel Filtration in Theory and Practice, Pharmacia Fine
Chemicals ). The two columns used in section 3.17 had volumes of
3.85 cm2 (100 mm x 7 mm diameter), and 5.53 cm2 (110 mm x 18
mm diameter), with sample volumes of 2 ml and 3 ml,
respectively. For good resolution with these columns the
maximum sample volumes of 0.2 ml and 0.28 ml should have been
applied. The sample volumes applied to these columns (section
3.17) were approximately 10 times greater than the volume
required for good resolution, and therefore inappropriate for good
resolution of serum components by these gel filtration columns. A
smaller sample volume may have improved separation of serum
components, however the IF-s separated into fractions may not
have been concentrated enough to detect a biological response.
Gel filtration of serum in section 3.17 did enable crude
extraction of IF-s activity into a small number of fractions,
eliminating a large proportion of other serum components, such
as albumin. These fractions could then have been used for more
2-i
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3.18 THE PRESENCE OF IF-s IS NOT REQUIRED DURING THE
PERIOD OF CELL CULTURE FOR INHIBITION BY
8-CI cAMP
3.18.1 Introduction:
The mechanism by which IF-s confers sensitivity of MCF-7
cells to 8-CI cAMP is not known. IF-s could be acting directly on
the cell making it sensitive to 8-CI cAMP, alternatively IF-s
could be combining with 8-CI cAMP to form an active complex or
IF-s could modify the drug into an active form. As previously
demonstrated in section 3.16, IF-s is unable to pass through the
10 kDa filter unit. In view of this, if IF-s combines to 8-CI cAMP
then the complex would not pass through the filter and the
filtrate would not show any activity. However, if IF-s activates
8-CI cAMP then this might be able to pass through the filter unit
and the filtrate would contain an antiproliferative effect even
though IF-s is not present.
3.18.2 IF-s Activates 8-CI cAMP:
To determine if IF-s activates 8-CI cAMP, HITS medium
containing 10% FCS (v/v) and 8-CI cAMP (10 pM) (3 ml) was
incubated for varying time periods at 37 oq. At each time point
the medium was centrifuged through a 10 kDa filter (section
2.11.1) and the filtrate collected for assaying for inhibitory
activity by thymidine uptake (section 2.1.6). The control for this
particular experiment was a volume of HITS medium containing
10% FCS (v/v) incubated for 72 hours in the absence of drug. A
sample with 8-CI cAMP was also incubated for 72 hours at 4 oc.
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The data in Figure 18 is expressed as a percentage of the
incorporation data for filtered medium incubated for 72 hours in
the absence of 8-CI cAMP. The results demonstrate that the
growth inhibitory activity can pass through the filter, and
incubation time increased the level of inhibition of [methyl-3H]
thymidine incorporation. The medium with drug incubated at 4 OC
for 72 hours had a level of inhibition equivalent to medium
incubated for 6-12 hours at 37 oq. Addition of 8-CI cAMP (10 pM)
to the time point zero medium did not produce an inhibitory
activity, suggesting that IF-s was removed by filtration (Figure
18). Addition of 8-CI cAMP (10 pM) to the other filtrate solutions
also showed no further effect on thymidine incorporation.
These data suggest that IF-s was not required to interact
directly with the cell to sensitize it towards 8-CI cAMP, since
filtration with a 10 kDa filter removed the factor. Moreover, the
data implies that IF-s does not complex to 8-CI cAMP since this
would not have passed through the filter. It is possible that IF-s
activates 8-CI cAMP conferring growth inhibitory properties to






Production of an active, filterable 8-CI cAMP derivative by
preincubation in serum containing medium.
HITS medium containing 10% FCS (v/v) and 8-CI cAMP (10 pM)
was preincubated at 37 °C for increasing periods of time before
filtering through a 10 kDa Centricon filter. The effect of this
medium was assayed by the incorporation of [methyl-3H]
thymidine with MCF-7 cells cultured for 78 hours. Control MCF-7
cells were cultured in HITS medium containing 10% FCS (v/v)
preincubated for 72 hours without drug before filtering (100%
incorporation).
Data are expressed as a percentage ± standard deviation of
quadruplicates, relative to incorporation by control.
* medium incubated at 4 OC for 72 hours.
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3.19 EFFECT OF IBMX ON 8-CI cAMP INHIBITION OF MCF-7
CELLS CULTURED IN HITS MEDIUM CONTAINING
10% FCS (V/V)
3.19.1 Introduction:
According to a recent report by Van Lookeren Campagne et al.
(1991), endogenous phosphodiesterases (PDE) a
5'-nucleotidases in serum can metabolise 8-CI cAMP, in the
absence of cells, to form a toxic 8-CI adenosine metabolite which
was responsible for the antiproliferative effect in their culture
system. This metabolism was demonstrated with 100 pM of drug.
It has been suggested however that a 10 pM concentration of
8-CI cAMP is below the concentration required to activate
phosphodiesterases (Cho-Chung, 1989).
3.19.2 Isobutvlmethvlxanthine (IBMX1:
To investigate the involvement of phosphodiesterases in the
growth inhibitory response of 8-CI cAMP, the general
phosphodiesterase inhibitor isobutylmethylxanthine (IBMX) was
added to culture medium. A stock solution of IBMX was dissolved
at a concentration of 5 mM in medium containing HITS. From this
IBMX was added to HITS medium containing 10% FCS (v/v) to give
a range of concentrations from 0.025 - 0.5 mM and assayed in the
presence of 8-CI cAMP (10 pM) by thymidine uptake (section
2.1.6). The controls for this experiment contained IBMX with no
8-CI cAMP.
IBMX in medium not containing 8-CI cAMP appeared to inhibit
thymidine uptake; for example 0.025 mM produced 27% inhibition
and 75% with 0.5 mM. However, in the presence of 8-CI cAMP
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(10 pM), all concentrations of IBMX used dramatically reduced the
inhibitory activity of the analogue (Figure 19). For example, in the
absence of IBMX, 8-CI cAMP inhibited growth by 81% of the
control and in the presence of 0.025 mM IBMX growth was only
inhibited by 25% of the control.
Even though increasing concentrations of IBMX inhibited
cellular proliferation, in the presence of 8-CI cAMP (10 pM)
growth inhibition was only approximately 25%. These
data suggest that PDE may be involved in the serum-dependent




The effect of isobutylmethylxanthine (IBMX) on the incorporation
of [methyl-3H] thymidine with MCF-7 cells cultured for 78 hours
in HITS medium containing 10% FCS (v/v) plus 8-CI cAMP (10 pM).
Control cells were cultured in the absence of 8-CI cAMP.
Data are expressed as a percentage ±_ standard deviation of
quadruplicates, relative to incorporation by control.
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3.20 EFFECT OF PDE ON MCF-7 CELLS CULTURED IN HITS
MEDIUM WITH 8-CI cAMP
3.20.1 Introduction:
The data from section 3.19 suggest that PDE may be involved in
the 8-CI cAMP growth inhibition. If PDE is responsible for the
8-CI cAMP antiproliferative effect then addition of these
enzymes to HITS medium with drug should confer growth
inhibition of MCF-7 cells.
3.20.2 Phosphodiesterases:
A crude preparation of PDE from bovine heart (1 unit will
hydrolyse 1.0 pM of cAMP to AMP per minute at pH 7.5 at 30 °C)
was dissolved in HITS medium at a concentration of 0.01 - 0.10
units per ml and assayed with MCF-7 cells for thymidine uptake
(section 2.1.6) in the presence or absence (controls) of 8-CI cAMP
(10 jiM).
In the presence of 0.01 units/ml of PDE, 8-CI cAMP inhibited
proliferation of MCF-7 cells by 95% relative to control (no drug;
100%). A further increase in the level of growth inhibition was
not evident with higher concentrations of PDE (Figure 20).
The inhibition with 0.01 units of PDE per ml was more
dramatic compared to previous observations with HITS medium
containing 10% FCS (v/v); approximately 80% inhibition. PDE
catalyse the conversion of cAMP to AMP; this observed growth
inhibition may be due to 8-CI AMP. However, the PDE was a crude
extract and may contain other enzymes which may metabolise




The effect of cAMP-dependent phosphodiesterases (PDE) on the
incorporation of [methyl-3H] thymidine by MCF-7 cells cultured in
HITS medium containing 10% FCS (v/v) plus 8-CI cAMP (10 piM)
for 78 hours.
Control cells were cultured in the absence of 8-CI cAMP.
Data are expressed as a percentage ± standard deviation of
quadruplicates, relative to incorporation by control.
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3.21 HPLC ANALYSIS FOR 8-CI cAMP METABOLITES
3.21.1 Introduction:
Data from sections 3.19 and 3.20 showed that IBMX can
partially block 8-CI cAMP induced inhibition of growth in serum
containing medium, and PDE can confer an 8-CI cAMP response in
HITS medium. Together these results implicate the involvement
of PDE in the mechanism of 8-CI cAMP inhibition of cellular
proliferation. To determine if serum PDE metabolise 8-CI cAMP in
culture the HPLC method described by Van Lookeren Campagne
et al. (1991) was employed (section 2.11.4).
3.21.2 Calibration:
Standards of 8-CI cAMP and 8-CI adenosine were dissolved in
distilled water and used to identify the retention times of the
drugs to the column and optimise conditions to produce good
resolution of the peaks. Each standard produced a distinct peak by
HPLC analysis suggesting there was little or no contaminating
products (Chromatogram 1). A flow rate of 1.4 ml/minute and a
30% methanol buffer (v/v) was eventually used to optimise the
system. Calibration plots were constructed from known
concentrations of standard 8-CI cAMP and 8-CI adenosine.
The peak areas for known concentrations of standard were
plotted to produce a calibration plot (Figure 21). The peak areas
detected appear to relate to the concentration of standard applied
to the column. The gradient of the line for both plots are very
similar, implying that equimolar concentration of both compounds
give equivalent peak areas. Standards were also dissolved in HITS
medium and produced identical plots compared to standard
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dissolved in water. Furthermore, no loss was found in peak area
for a concentration of standard centrifuged through a 10 kDa
filter unit, demonstrating that these compound are free to pass
through the filter.
3.21.3 Metabolism Of 8-CI cAMP Bv FCS:
To investigate if 8-CI cAMP was metabolised by FCS, HITS
medium containing different concentrations of FCS was incubated
at 37 OC with either 100 pM or 10 pM 8-CI cAMP for 72 hours. The
media was centrifuged through a 10 kDa Centricon filter to
remove the majority of the FCS proteins, and the filtrate diluted
1 : 20 with running buffer (section 2.11.3) before analysis by
HPLC (section 2.11.4). Standard calibration plots were also
constructed.
Chromatogram 1 shows an overlay plot of two samples:
200 pM of 8-CI cAMP and 8-CI adenosine standard dissolved in
water; and a 100 pM 8-CI cAMP sample incubated for 72 hours in
HITS medium containing 10% FCS (v/v). The peaks eluted from the
column before four minutes were also present in HITS medium
alone. The only peak, apart from 8-CI cAMP, that appeared after
incubating drug in serum containing medium, corresponded to the
8-CI adenosine standard (i.e. identical retention times on the
column). The concentration of the 8-CI adenosine associated
peaks is plotted in Figure 22 against the concentration of serum.
The concentration of the 8-CI adenosine associated peak in
medium appears to increase with respect to the serum content
with both starting concentrations of 8-CI cAMP. No metabolite
peak was detected with either concentration of 8-CI cAMP
incubated in HITS medium.
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This data confirms the report by Van Lookeren Campagne et al.
(1991) that a metabolite of 8-CI cAMP (100 pM) is produced in
medium containing serum. However, this data also demonstrates
that 10 pM 8-CI cAMP is also metabolised in serum conditions.
These data suggest that for previous experiments with MCF-7
cells cultured in HITS medium containing 10% FCS (v/v) and 8-CI
cAMP (10 pM), a metabolite, possibly 8-CI adenosine was
metabolised to a concentration of approximately 8 pM after a 3
day incubation. Furthermore, the concentrations of detectable
metabolite found in medium with different amounts of serum
appear to correlate with data that demonstrate the level of




A representative chromatography trace of 8-CI cAMP and
8-CI adenosine standards (200 pM) (Blue trace) overlaid with a
plot for a sample of HITS medium containing 10% FCS (v/v) plus 8-
Cl cAMP (100 jiM) incubated at 37 oc for 72 hours (Red trace) (see
section 3.21.3).
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Peak areas detected by HPLC for known concentrations of 8-CI
cAMP and 8-CI adenosine in H2O (see section 3.21.2).
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%FCS (v/v) in HITS/Medium
FIGURE 22:
The concentration of an 8-CI adenosine associated metabolite
peak (see Chromatogram 1) detected by HPLC analysis in HITS
medium containing 10% FCS (v/v) plus 8-CI cAMP incubated at
37 OC for 72 hours.
Medium was filtered through a 10 kDa Centricon filter before
analysis by HPLC.
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3.22 CONFIRMATION THAT THE METABOLITE PEAK IS
8-CI ADENOSINE
To confirm that the 8-CI adenosine associated metabolite peak
from section 3.21.3 was related to 8-CI adenosine the metabolite
peak and standards were spectrally analyzed with the HP1090
(Hewlett Packard). This HPLC equipment can monitor a range of
wavelengths for a single sample giving a spectral pattern (or
profile) for each peak. The spectral absorbance for each peak was
monitored over 200 - 400 nm.
Chromatogram 2 shows that the profile for 8-CI cAMP, 8-CI
adenosine and the metabolite peak were identical. Absorbance is
due to the adenine ring giving it this characteristic spectral
profile. This data confirms that the metabolite peak contains an
adenine ring. Furthermore, the identical retention times for the
metabolite and 8-CI adenosine (see chromatogram 1) also support
that this peak is 8-CI adenosine. It is unlikely that the identity of
this metabolite peak is due to another metabolite of 8-CI cAMP
such as 8-CI AMP or 8-CI inosine, since these have different




UV absorbance (normalised to maximum absorbance; 100%) of
8-CI cAMP (BLUE), 8-CI adenosine (RED) and an 8-CI cAMP
metabolite (GREEN; see section 3.22) over a wavelength range of
200 - 400 nm.
300Havelength
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3.23 CONCENTRATION DEPENDENT FORMATION OF
METABOLITE WITH cAMP ANALOGUES
3.23.1 Introduction:
Data presented in section 3.14 demonstrated that 8-CI cAMP
was a more potent antiproliferative agent than 8-Br cAMP
cultured in serum containing conditions (compare Figure 12 &13).
Evidence presented in this thesis suggest that the
antiproliferative effect of 8-CI cAMP is due to production of a
metabolite, therefore suggesting that the antiproliferative effect
of 8-Br cAMP may also be due to a metabolite. The different
potencies of these two analogues could be explained by a higher
rate of metabolism for 8-CI cAMP compared to 8-Br cAMP.
3.23.2 Rate of 8-CI cAMP and 8-Br cAMP Metabolism In
HITS Medium Containing 10% FCS fv/vl:
A range of 8-CI cAMP and 8-Br cAMP concentrations were
incubated in HITS medium containing 10% FCS (v/v) for 72 hours
at 37 OC. The medium was filtered (section 2.11.3) before HPLC
analysis (section 2.11.4). Pure 8-Br adenosine was not available
to construct a calibration plot for peak area against
concentration. However, since 8-CI adenosine and 8-CI cAMP gave
similar calibration plots (see Figure 21), and the only difference
between the two cAMP analogues is the halogen, then the molar
absorbance for 8-Br cAMP could be used to calculate a
concentration for the metabolite peak areas.
HPLC analysis of medium incubated with 8-Br cAMP showed
two peaks; one known to be 8-Br cAMP and the other assumed to
be 8-Br adenosine. The concentration of both 8-CI adenosine and
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the putative 8-Br adenosine, shown in Figure 23, demonstrate
that similar concentrations of both metabolites were formed in
the medium. Furthermore, this production appeared to be
dependent on the starting concentration of the cAMP analogue;
rate of hydrolysis works out to be-
85 pM metabolite/ 390 pM cAMP analogue/ minute
(Derived from Figure 23).
These data suggest that metabolism of both analogues are
equivalent and therefore does not provide an explanation for their
different potencies. Nevertheless, comparison of the growth
inhibition data for different concentrations of analogue (Figure
12 & 13) with this data (Figure 23) suggest that the
concentration of the metabolite correlates with the level of




The formation of 8-CI adenosine and 8-Br adenosine in HITS
medium containing 10% FCS (v/v) plus cAMP analogue incubated
for 72 hours at 37 OC.
Medium was filtered through a 10 kDa Centricon filter before
analysis by HPLC.
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3.24 EFFECT OF INCUBATION TIME ON METABOLITE
FORMATION
Data from section 3.18 suggested that IF-s activated 8-CI
cAMP, enabling the drug to inhibit cellular proliferation in serum-
free conditions, and that the degree of inhibition was time
dependent. To determine if this growth inhibition was due to
formation of 8-CI adenosine these filtrates were analyzed by
HPLC (section 2.11.3 & 2.11.4) .
8-CI adenosine was detected in these samples. The
concentration increased from 3 hours to 12 hours (Figure 24).
Metabolite concentration in samples incubated for longer periods
did not appear to increase further, apart from the 72 hour
incubation. Even though no relationship appears to exist for time
and concentration of metabolite for this data, the presence of
metabolite in the media still correlates with the effect on
cellular proliferation (section 3.18). Furthermore, the medium
incubated at 4 oc for 72 hours had 93% less detectable 8-CI
adenosine compared to the sample incubated at 37 oc.
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FIGURE24: Theformationf8-CIadenosineinHITSmediumcontai ing10%FC(v/v)plu- IAMP10ji incubateda37OCforvaryingtimperiods.Th sd tisalsos l yedwitht ehy idinuptak fromsection3.18(s eFigur18legend).
3.25 IBMX INHIBITS THE GENERATION OF 8-CI ADENOSINE
FROM 8-CI CAMP BY SERUM
Addition of IBMX to culture medium containing serum reduced
the ievel of inhibition by 8-CI cAMP (section 3.19). To determine
if this protective effect of IBMX was the result of reducing the
concentration of 8-CI adenosine formed, HITS medium containing
10% FCS (v/v) was incubated for 72 hours with either 100 pM or
10 pM 8-CI cAMP in the presence or absence (control) of a range
of IBMX concentrations. Samples were prepared (section 2.11.3)
and analyzed by HPLC (section 2.11.4).
Incubation of 100 pM 8-CI cAMP in the presence of 0.025 mM
IBMX resulted in the reduction of 8-CI adenosine from 19 pM to
7 pM (Figure 25). A further, but smaller, decrease in the
concentration of 8-CI adenosine was observed with increasing
concentrations of IBMX. Furthermore, concentrations above 0.025
mM resulted in no detectable 8-CI adenosine when a starting
concentration of 10 pM 8-CI cAMP was incubated in the medium
(Figure 25).
These data suggest that the protective effect of IBMX against
the antiproliferation response of 8-CI cAMP (section 3.19; Figure





















The Effect of isobutylmethylxanthine (IBMX) on the formation of 8-
Cl adenosine in HITS medium containing 10% FCS (v/v) and 8-CI
cAMP incubated at 37 °C for 72 hours.
Medium was filtered through a 10 kDa Centricon filter before
analysis by HPLC.
158
3.26 THE EFFECT OF PDE ON METABOLISM OF 8-CI cAMP IN
SERUM-FREE MEDIUM
Addition of the crude PDE preparation to HITS medium induced
an 8-CI cAMP inhibition on MCF-7 cells (section 3.20). To
determine if the growth inhibitory effect produced by crude PDE
was due to 8-CI AMP formation, HITS medium containing PDE
(0.01 - 0.1 units / ml) and 8-CI cAMP (100 ]iM) was incubated for
72 hours at 37 OC. The media was then prepared (section 2.11.3)
for HPLC analysis (section 2.11.4). Standard for 8-CI AMP was not
available. Nevertheless, the formation of a new metabolite peak
such as 8-CI AMP can be monitored because of different retention
times for metabolites, but the identity of additional peaks can
only be assumed.
At 0.04 units/ml of PDE all detectable 8-CI cAMP was
completely metabolised; 8-CI adenosine was also detectable.
However, higher concentrations of PDE resulted in a decrease in
the concentration of 8-CI adenosine. Formation of two new
metabolite peaks were identified that had shorter retention
times to the column than that of 8-CI cAMP or 8-CI adenosine.
These two peaks where not detected in previous samples
containing serum and nor were they detected in medium
containing PDE alone. Based on the retention times report by Van
Lookeren Campagne's group (1991) for 8-CI cAMP metabolites, the
additional peaks eluted from the column were probably 8-CI AMP
and 8-CI inosine.
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These data confirm that this crude PDE metabolizes 8-CI cAMP to
more than just 8-CI AMP, suggesting that the preparation
contains other metabolising enzymes including nucleotidase due
to the formation of 8-CI adenosine.
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3.27 METABOLITE OF 8-CI cAMP MEDIATED BY FCS
FRACTIONS
Gel filtration of concentrated FCS yielded a number of
fractions that contained a high activity of IF-s (section 3.17). To
establish if the activity from these fraction was proportionate to
the formation of 8-CI adenosine, fractions from these two
columns were added at 10% (v/v) to medium containing FIITS.
8-CI cAMP (50 pM) was incubated for 72 hours in this media and
analyzed for metabolite formation by HPLC (section 2.11.3 &
2.114).
Figures 26 and 27 show the concentration of 8-CI adenosine
formed for each fraction, combined with the data previously
shown for the protein concentration of the fractions and the
percentage of thymidine incorporation (section 3.17; Figures 16 &
17, respectively). Those fractions that were demonstrated to
contain the major IF-s activity also appeared to have the highest
concentrations of 8-CI adenosine.
These data show that the fractions, thought to contain the
highest concentrations of IF-s, have the highest concentrations
of PDE and 5'-nucleotidase activity. This suggests that the































FIQURE2g; Theformationf8-CIadenos neinHITSmediumcont i i g10%FCSfra tio(v/v)se tion3.17.2)plus 8-CIcAMP(50p )incubateda37ofor72h rs. Mediumwasfilt redthrougha10kDCentriconfil rb fa alysisHPLC. Thymidineincorporationanp oteinc nce tr t od tfrigur16(selege d).
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FIGURE27: Theformationf8-CIadenosineinHITSmediumconta ni g10%FCSfractions(v/v)(section3.17.3)plus 8-CIcAMP(50p )incubateda37of r72h urs. Mediumwasfilteredthrougha10kDaCen r c nfiltebeforeanalysisbHPLC. Thymidineincorporationandpr teinconcentrationdatfromfigure17(seelegend).
3.28 METABOLISM OF 8-C1 cAMP BY OTHER SERA
3.28.1 Human Serum:
Fresh human blood was used to prepare serum to determine if
it possessed IF-s activity and metabolized 8-CI cAMP. The human
serum was added to HITS medium to give different concentrations
and incubated with 8-CI cAMP (100 pM) at 37 oc for 72 hours. The
media was then prepared (section 2.11.3) and analyzed by HPLC
(section 2.11.4). In addition, the media was also used for the
thymidine uptake assay (section 2.1.6) in the presence or absence
(control) of 8-CI cAMP (10 pM).
Figure 28 shows the combined data for thymidine uptake and
concentration of 8-CI adenosine. The degree of inhibition of
thymidine incorporation appears to be dependent on the
concentration of human serum in the medium. Furthermore, this
growth inhibition correlated with the concentration of
8-CI adenosine. A maximum of approximately 60% inhibition was
demonstrated with 10%; this compares with approximately 80%
for FCS and may be explained on the bases of 8-CI adenosine
formation (see 3.28.2).
3.28.2 Mouse Serum:
Using nude mouse serum, a 10% (v/v) solution in HITS medium
was incubated at 37 oc with 8-CI cAMP (100 pM) for 72 hours.
By HPLC analysis 31 pM of 8-CI adenosine was detected. This
compares with a value for 10% (v/v) FCS and human serum of 22
pM ± 3.5 (n=3) and 10 pM, respectively.
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FIGURE28: Theeffectof8-CIcAMP(10p )nthincorporationf[met yl-3H]thymidinbMCF-7c llsultur dHITSmediumnta i g differentconcentrationsfhumaserum(v/v)f78ou s. Controlcellsw enottreatedi h8-CIcAMP(i. .100%). Dataareexpressedpercen age±standarddevi tionofqu druplicates,rel vtincorpo atiobycontr l. Theformationf8-CIadenosineinHITSmediumconta ni gdiffere tco cen r tio sfhu ns rum(v/v)a d8-CIcAMP(100p ), incubateda37OCfor72h rs. Mediumwasfilt redthrougha10kDCentriconf erb f rea alysisHPLC.
3.29 INHIBITION OF THYMIDINE UPTAKE BY
8-CI ADENOSINE
To demonstrate that 8-CI adenosine was toxic to MCF-7 cells
an experiment was set up adding concentrations of 8-CI adenosine
or 8-CI cAMP to HITS medium or HITS medium containing 10% FCS
(v/v) and assayed with MCF-7 cells for inhibition of thymidine
uptake (section 2.1.6).
8-CI adenosine dramatically inhibited thymidine uptake both in
HITS and serum containing medium (Figure 29). 8-CI cAMP, as
previously demonstrated, did not inhibit uptake in HITS medium
but inhibition of thymidine incorporation increased with respect
to concentration of drug added to serum containing medium.
These data demonstrate that 8-CI adenosine inhibits
proliferation of MCF-7 cells in HITS medium, in the presence or
absence of serum. The apparent IC50 for 8-CI adenosine in HITS
medium containing serum is equivalent to the value quoted by
Katsaros et al. (1988) of 1 pM (see section 3.2.1). Furthermore,
the inhibition of MCF-7 cells cultured in HITS medium containing
10% FCS (v/v) by 8-CI adenosine was more effective at equimolar




The effect of different concentrations of 8-CI adenosine or 8-CI
cAMP on the incorporation of [methyl-3H] thymidine with MCF-7
cells cultured for 78 hours in HITS medium either in the presence
or absence of 10% FCS (v/v).
Control cells were cultured in the absence of drug (i.e. 100%
incorporation).
Data are expressed as a percentage ±. standard deviation of





4.1 Hormone-Responsive MCF-7 cells
MCF-7 cells have been used extensively as a model for hormone-
responsive breast cancer since they were established in the early
1970s (Soule et al., 1973). These cells can be cultured in a
variety of different media and sera and many researchers have
adopted different conditions for maintaining this cell line.
Consequently, numerous clones of MCF-7 cells have developed
which have varying population doubling times, oestrogen receptor
content and responsiveness to oestrogen and tamoxifen (Butler et
al., 1981; Page et at., 1983; Katzenellenbogen et at., 1987). The
initial aim of the thesis was to investigate the mechanism of
antagonism by 8-CI cAMP of oestradiol growth stimulation in MCF-
7 cells, as described by Katsaros et al. (1988). Their MCF-7 cells
were not used and it was therefore necessary to develop culture
conditions and demonstrate the hormone-responsiveness of the
cells used in this study. The hormone-responsiveness of these
cells was demonstrated in medium containing 1% charcoal-
stripped FCS (v/v) by 10-9 and 10-s M oestradiol (section 3.1);
population doubling time decreased from 4 days to 2 days. This
two fold stimulation was similar compared to Katsaros's MCF-7
cells, even though their cells had a basal growth level of 8 days
in medium containing 6.5% charcoal-stripped FCS (v/v). Addition
of tamoxifen (5 x 10-7 - 10-6 M) and retinoic acid (10-6 M)
appeared to antagonise this oestradiol stimulation of our cells.
The serum concentration used by Katsaros et al. (1988) was not
duplicated, since our MCF-7 cells showed typical responses to
oestradiol, tamoxifen and retinoic acid in 1% conditions.
Furthermore, this lower concentration of serum used in our
culture system ensured that endogenous steroids (not removed by
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charcoal-stripping) and other growth promoting factors were
kept to a minimum, therefore allowing closer examination of the
effects that exogenous agents had on the proliferation of the
cells in culture.
4.2 Mechanism Of Tamoxifen Antagonism
Tamoxifen was originally developed as a competitive inhibitor
for the binding of oestradiol to its receptor, thus preventing
activation and eventual stimulation of proliferation. However,
there is accumulating evidence suggesting that tamoxifen can
modulate proliferation other than by antagonism of the oestradiol
response. Butler et al. (1981) demonstrated that in the absence of
added oestradiol, growth inhibition of MCF-7 cells by tamoxifen
(1 pM) was more effective at low concentrations of charcoal-
stripped serum (0.1 - 1% (v/v)) than at higher concentrations of
serum (10% (v/v)). They also demonstrated that the degree of
stimulation by oestradiol (5 x 10-s M) diminished as the
concentration of serum increased. Vignon et al. (1987) also
demonstrated that hydroxytamoxifen (1 pM) inhibited the
proliferation of MCF-7 cells in the complete absence of
oestradiol in the medium. However, this antiproliferative effect
did require the presence of oestradiol receptors, since this effect
could not be demonstrated in cells lacking oestradiol receptor.
Other reports have also suggested that addition of tamoxifen can
stimulate MCF-7 cells and alter expression of gene products that
do not appear to be regulated by oestradiol (May et al., 1989;
Westley et al., 1989). Our MCF-7 cells had tamoxifen regulated
proteins that did not appear to be controlled by oestradiol
(section 3.6.3). Treatment of MCF-7 cells with tamoxifen (1 pM)
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resulted in the expression of three proteins detected by Western
blotting with the monoclonal antibody BA17 against cytokeratin
19. Only two of these proteins appeared to be expressed in the
presence or absence of oestradiol and expression was much lower
than for tamoxifen treated MCF-7 cells. Similar patterns of
protein staining in control cells and oestradiol treated cells
suggest that oestradiol does not affect the expression of these
proteins and tamoxifen can. The mechanism of this is unknown;
however, expression of these three proteins could be a
consequence of the antiproliferative effect of tamoxifen. On the
other hand, the antiproliferative effect of retinoic acid does not
induce the same changes in expression of these proteins as does
tamoxifen.
4.3 8-CI cAMP Antagonism of Oestradiol Stimulation in
MCF-7 cells
Katsaros et al. (1988) demonstrated that 8-CI cAMP (1 pM)
produced a 50% growth inhibition of MCF-7 cells stimulated by
oestradiol (10-8 M) after a period of 5 days. In contrast, addition
of ten times the concentration of 8-CI cAMP (10 pM) to our MCF-7
cells in 1% FCS conditions produced no dramatic alteration in
proliferation in the presence or absence of oestradiol (section
3.2.2). Hypothetical^, according to observations by Butler et al.
(1981) with tamoxifen, a lower concentration of serum and a
higher concentration of 8-CI cAMP would have been expected to
have a greater inhibition of MCF-7 cells after 5 days than that
reported by Katsaros et al. (1988). Using HITS as a serum
substitute in the medium, MCF-7 cells had a doubling time of 2
days in culture and did not appear to respond to exogenous
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oestradiol or 8-CI cAMP (section 3.11). This apparent loss of
hormone-responsiveness in serum-free conditions has previously
been observed by Katzenellenbogen et al. (1987). They cultured
MCF-7 cells for 5 to 6 months in phenol red free and charcoal-
stripped FCS conditions, essentially devoid of oestradiol.
Addition of oestradiol to the cells after this period of time did
not produce a hormone response in cells that were initially
responsive. Plowever, an antiproliferative effect by 8-CI cAMP
was demonstrated with MCF-7 cells used in this study when
cultured in conditions containing 10% FCS (v/v), charcoal-
stripped or unstripped (section 3.3). Furthermore, as the
concentration of serum in the medium decreased then so did the
level of inhibition by 8-CI cAMP (10 pM) (sections 3.3, 3.11 &
3.13). In addition, the level of growth inhibition by 8-CI cAMP
appeared to be similar in the presence or absence of oestradiol,
regardless of the serum concentration in the medium (section
3.3). These data suggested a serum-dependent 8-CI cAMP growth
inhibition of MCF-7 cells, but no direct antagonism of the
oestradiol growth stimulation. Compared to the report of
Katsaros et al. (1988); they did not investigate the effects of 8-
Cl cAMP on MCF-7 cells cultured in the absence of oestradiol or in
serum-free conditions. It is distinctly possible that the observed
inhibition of growth was misconstrued as antagonism, and they
may have demonstrated similar data as presented in this thesis if
growth inhibition by 8-CI cAMP was studied in the absence of
oestradiol or serum-free conditions.
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4.4 p21. Kinase A Regulatory Subunits and Cell Cvcle
Analysis
A decrease in the expression of p21 has been observed with
tumours and cell lines growth inhibited by cAMP analogues. This
concomitant decrease in p21 on growth inhibition was also
associated with a change in the expression ratio of Rl and Rll
subunits of protein kinase A (see Introduction). However, in
experiments presented here, alteration in the expression of p21
and Rl : Rll levels in MCF-7 cells growth inhibited by 8-CI cAMP
were not detected (section 3.7 & 3.8), in contrast to previous
reports by Tagliaferri et al. (1988) and Katsaros et at. (1988). It
is possible that this clone of MCF-7 cells is sufficiently
different from these authors cells to alter the mechanism by
which 8-CI cAMP modulates p21 and Rl : Rll expression ratio. This
would suggest that the change in expression of p21 and Rl : Rll is
not a prerequisite for growth inhibition by 8-CI cAMP. The cell
cycle progression data (section 3.9) also suggest differences in
the mechanism. Growth inhibition of MCF-7 cells by 8-CI
cAMP produced a block in G2 + M phase which has not been
previously observed (Tagliaferri et al., 1988).
Despite the differences, the antiproliferative effect of 8-CI
cAMP was qualitatively similar in our cells to previous reports.
However, this effect appeared to be dependent on the
concentration of serum in the culture medium, an observation not
reported. This serum-dependent 8-CI cAMP growth inhibition was
not a phenomenon exclusive to MCF-7 cells since it was also
demonstrated in other cell lines (section 3.12).
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4.5 Serum-Deoendent 8-CI cAMP Growth Inhibition
The observation that 8-CI cAMP (10 pM) growth inhibition was
dependent on the concentration of serum in medium led to the
thesis that a serum-borne component was required in combination
with 8-CI cAMP to inhibit cellular proliferation. This putative
serum factor(s) (IF-s) was also present in charcoal-stripped
serum (section 3.3). Many studies (including Katsaros et al., 1987;
Tagliafferi et al. 1988; Tortora et at., 1988; Guadagni et at.,
1991) using the site-selective analogue 8-CI cAMP on cancer
cells have assayed for growth inhibition in medium containing
different serum concentrations from 5 to 10% FCS (v/v). The
growth inhibition reported by these authors was considered
entirely due to the affect of the drug on the cell, however, a
serum-dependent 8-CI cAMP growth inhibition may have been
present. There are reported cases of site-selective analogues
affecting the Harvey murine sarcoma virus transformed NIH/3T3
fibroblast line in serum-free medium (Tagliaferri et al., 1985;
Tagliaferri et al., 1988). It is therefore likely that there are some
cancer cell lines, like these fibroblasts, that respond directly to
cAMP analogues without the need for the putative serum
factor(s) IF-s.
4.6 Characterisation of IF-s
The data in section 3.15 demonstrated that IF-s in FCS was
heat labile, suggesting that IF-s might be a protein. Heat
inactivation appeared to occur between the temperatures of 56 OC
and 60 c>C. We attempted initially to isolate a serum fraction
enriched in IF-s. Early experiments demonstrated that IF-s could
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not pass through the 100 kDa Centricon filter (section 3.16) and
suggested that its molecular weight was greater than 100 kDa.
However, PAGE analysis of the concentrate and filtrate suggested
that these filters have poor fidelity under these conditions in
selectively isolating proteins of molecular weights according to
the filters nominal cut off size. Only a small proportion of the
serum albumin (molecular weight 67 kDa) passed through the 100
kDa cut off filter. It is possible that because of the high
concentration of albumin in the serum, the filter could have
become blocked. Alternatively, albumin may be associated with
other proteins, including itself, giving an apparent molecular
weight in serum of greater than 100 kDa during filtration.
Because, the reliability of these molecular weight cut off filters
was in doubt, it was in any case not possible to conclude that the
molecular weight of IF-s is greater than 100 kDa.
Gel filtration chromatography of the 10 kDa concentrate,
through two individual columns, gave profiles with the majority
of the inhibitory activity appearing in the early fractions (section
3.17). IF-s was not eluted in a sharp peak; activity slowly
diminished in fractions eluted after the major activity. This may
simply reflect the low resolving power of the column used.
Alternatively, IF-s may be composed of species of heterologous
molecular weights. The largest protein peak eluted from the
column was probably due to the most abundant protein in the
serum, albumin and fractions eluted from the column before this
peak have a higher molecular weight. The majority of IF-s was
eluted in these early fractions, well before albumin, suggesting
that it has a molecular weight well in excess of 67 kDa.
The experiment in section 3.18 demonstrate that preincubating
8-CI cAMP in serum containing medium produced a time-
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dependent activation of the drug. This activated species could
then be separated from IF-s by 10 kDa ultrafiltration. The facts
that: IF-s appeared to activate 8-CI cAMP in a time-dependent
manner; the rate of activation was lower at 4 OC; IFs is heat
labile (section 3.15), strongly implies that IF-s might be an
enzyme(s).
NB: It was at this stage of the thesis that the data of
Van Lookeren Campagne et al. (1991) were published.
4.7 Metabolism of 8-CI cAMP
In a recent article (Van Lookeren Campagne et al., 1991),
evidence was presented that 8-CI cAMP (100 pM) was
metabolised in medium containing 10% FCS (v/v) incubated for 3
days at 37 oc, in the absence of cells. The authors suggested that
the endogenous phosphodiesterases and 5'-nucleotidases in serum
were converting the drug to the toxic metabolite 8-CI adenosine.
In contrast, Tagliaferri et al. (1988) reported that no detectable
8-CI adenosine, as measured by HPLC, was present in 10% FCS
(v/v) medium used to culture HT-29 cells treated with 8-CI cAMP
(50 pM) for 48 hours. Van Lookeren Campagne's group stated that
this discrepancy could have arisen from the use of inappropriate
methodology for HPLC analysis of 8-CI adenosine. They stated
that the pH buffer (pH 3.8) used by Tagliaferri et al. (1 988)
resulted in a net positive charge on 8-CI adenosine, which
therefore would not be retained by the strong ion exchange
column. Van Lookeren Campagne's group concluded that 8-CI cAMP
growth inhibition of Chinese hamster ovary (CHO) cells and Molt-4
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cells cultured in 10% FCS (v/v) medium was mediated through 8-
Cl adenosine. Again in contrast, however, Tortora et at. (1988)
reported that addition of phosphodiesterase inhibitors, IBMX (0.5
mM) or theophylline (0.1 mM), did not affect the inhibitory
effect of 8-CI cAMP (5 - 20 pM) on a spectrum of leukaemic cells
including Molt-4 cells, cultured in 10% FCS (v/v) media. The fact
that the inhibitory activity of 8-CI cAMP was not affected in
these conditions suggested to the authors that
phosphodiesterases were not metabolizing the drug. On the other
hand, if 8-CI adenosine was responsible for the inhibitory
response of 8-CI cAMP then addition of phosphodiesterase
inhibitors should have prevented the growth inhibitory effect of 8-
Cl cAMP in these culture conditions. However, addition of IBMX
(0.025 - 0.5 mM) to our MCF-7 cells cultured in 10% FCS (v/v) did
not enhance the 8-CI cAMP response but reduced it (section 3.19).
Furthermore, cells cultured in HITS were growth inhibited by 8-CI
cAMP in the presence of phosphodiesterase (section 3.20). These
data appear to contradict their observation. Using Van Lookeren
Campagne's HPLC method, 8-CI adenosine was detected in serum
containing medium with only 10 pM 8-CI cAMP (section 3.21.3).
This demonstrated that a concentration of 10 pM 8-CI cAMP,
previously suggested by Tagliaferri et at. (1988) and Cho-Chung
(1989) to be too low for metabolism by phosphodiesterases, was
metabolised to 8-CI adenosine. The concentration of 8-CI
adenosine in the medium also appeared to correlate with degree
of growth inhibition of MCF-7 cells induced by 8-CI cAMP (section
3.21.3; further discussed in section 4.9).
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4.8 Adenosine Toxicity
Adenosine is a purine nucleoside that is an intermediate in the
pathway of purine nucleotide degradation. In addition to
adenosine's physiological role in cellular biochemistry (eg. AMP,
ATP), high concentrations in the range of 1 - 1000 pM are known
to be toxic to mammalian cells (Green & Chan, 1973; Ullman et
al., 1976; Hershfield et al., 1977). The precise mechanism of
adenosine toxicity is not clearly understood but it has been shown
that high concentration can affect the activity of enzymatic
reactions involved in the synthesis and degradation of purines and
pyrimidines. Studies have shown that adenosine can reduce the
activity of orotate phosphoribosyltransferase and this leads to
depletion of the pyrimidine nucleotide pool (Planet & Fox, 1977;
Ishii & Green, 1973; Kaukel et al., 1972). Adenosine has also been
reported to reduce the intercellular concentration of 5-
phophoribosyl-1-pyrophosphate (PRPP) (Snyder & Seegmiller,
1976; Planet & Fox, 1976). PRPP is an essential substrate in
purine and pyrimidine de novo biosynthesis, the purine salvage
pathways and pyrimidine nucleotide synthesis (Fox & Kelly,
1971). A decrease in PRPP can, therefore, have a profound
metabolic effect on the cell, especially DNA synthesis.
The toxicity of 8-CI adenosine was demonstrated with a range
of concentrations (1 - 20 pM) with MCF-7 cells cultured in the
presence or absence of serum (section 3.29). This compares with
reports that demonstrated toxicity with 2 and 5 pM (Katsaros et
al., 1988; Tagliaferri et al., 1988). These authors also showed
that 8-CI adenosine induce a cell cycle progression block in S
phase of LS-174T cells, and this growth inhibition did not result
in a change in p21 and Rl : Rll levels. These effects of 8-CI
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adenosine appear to be similar to those described for 8-CI cAMP
in this thesis. Though the limited availability of 8-CI adenosine
prevented studies on p21, Rl, Rll and cell cycle analysis, the data
presented here do suggest that the 8-CI cAMP response is
mediated by the metabolite 8-CI adenosine, as suggested by Van
Lookeren Campagne's group. They also showed that 8-CI adenosine
inhibited their CHO cells, but an equimolar concentration of 8-CI
cAMP proved more potent in serum containing medium. The
authors attempted to explain this as due to 8-CI cAMP acting on a
reservoir for the release of cellular adenosine. Our MCF-7 cells,
on the other hand, appear to be two fold more sensitive to 8-CI
adenosine than 8-CI cAMP (section 3.29). If adenosine was
released from intracellular reservoirs as a result of added 8-CI
cAMP, it did not appear to play a role in the inhibition of our cells
since no inhibition was observed with cells cultured in HITS
medium with drug. In serum containing culture conditions,
however, addition of a concentration of 8-CI adenosine is
probably more effective than 8-CI cAMP at inhibiting the MCF-7
cells because production of the metabolite appears to be time-
dependent (sections 3.18 & 3.24).
The conflicting data from Van Lookeren Campagne et al. (1991)
and this thesis, compared to other workers on the action of 8-CI
cAMP is difficult to explain. The two serum-free studies which
demonstrated a cAMP analogue^cannot be explained by metabolism
of the drug in the media (Tagliaferri et al., 1985; Tagliafferi et
al., 1988). However, it is possible that the analogues were
hydroiysed by cellular phosphodiesterases. All other studies have
been performed in media containing serum. Van Lookeren
Campagne's group (1991) studied different batches of FCS and
other sera for hydrolysis of 8-CI cAMP and found that they all
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degraded the drug, but the rate of hydrolysis varied: 2% hydrolysis
for human serum; 28 - 72% hydrolysis for other sera. The authors
also showed that heat-inactivation of FCS reduced the level of
activity by at least 6 fold. Though only heat-inactivated FCS was
used in this thesis, the data presented in section 3.15 support
this observation, since the activity of the hydrolysing enzymes in
serum was denatured at 60 OC. It is possible that other workers
used sera with a low hydrolysis activity or denatured all
hydrolysing activity by heat-inactivating their sera, therefore
producing culture conditions that did not hydrolyse 8-CI cAMP.
This seems unlikely since data from this thesis show that 8-CI
cAMP in medium with heat denatured serum or HITS does not
inhibit cellular proliferation (section 3.15). Alternatively, it is
possible that other studies used cells that were sensitive to 8-CI
cAMP. This also seems improbable since a total of five
established cell lines, including three lines previously
demonstrated to be inhibited by 8-CI cAMP, appeared to be
insensitive to the drug in the serum-free conditions (section
3.12). Previous reports of growth inhibition by 8-CI cAMP was
probably due to formation of 8-CI adenosine. However, the
antiproliferative effect may have been due to not only 8-CI
adenosine but also 8-CI cAMP if the cell line was directly
sensitive to the analogue. The reported changes in p21 and Rl : Rll
expression ratio by 8-CI cAMP, which could not be demonstrated
in our MCF-7 cells, may have been due to a direct affect of 8-CI
cAMP on cells.
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4.9 Phosphodiesterases (PDE) And 5'-Nucleotidases
Early literature concerning PDE degradation of cAMP analogues
typically refers to the PDE located within the cell and not to PDE
in mammalian sera, which have been recognised since the early
1970s (Asano & Hidaka, 1975).
Cells contain three basic types of cAMP-dependent
phosphodiesterase with different affinities for cAMP. These
enzymes occur as integral parts of the cell membrane and also as
soluble enzymes in the cytoplasm. The soluble form is activated
by Ca2+ acting through calmodulin (Martin, 1987; pp. 133-134).
However, calmodulin is not required to activate species found in
mammalian sera (Asano & Hidaka, 1975). These PDE, isolated from
rabbit, rat, dog and human sera, have a molecular weight range
from 150 to 340 kDa. Asano and Hidaka (1975) studied the enzyme
kinetics of these and calculated the Km values for cAMP
hydrolysis which ranged from 0.81 - 76 pM. Furthermore, they
calculated the PDE activity with 0.4 pM cAMP, which ranged from
1.60 - 172 pmoles/min/ml. The molecular weights for these PDE
support the chromatography data (section 3.17) which suggest
IF-s has a molecular weight greater than 67 kDa. Furthermore,
the Km values suggest that mammalian sera phosphodiesterase
could be activated by concentrations of 8-CI cAMP used in the









The above diagram represents the biochemical pathway for the
formation of 8-CI inosine from 8-CI cAMP, with the appropriate
enzyme for each reaction indicated. The presence of 5'-
nucleotidase in serum was deduced since the only peak detected
by HPLC when 8-CI cAMP was incubated in medium containing FCS
was 8-CI adenosine (chromatogram 1; section 3.21). 5'-
nucleotidases have an approximate molecular weight of 140 kDa
for the native enzyme (Chuang et al., 1984). The gel filtration
profile is thus consistent with IF-s being comprised of serum PDE
and 5'-nucleotidase.
Addition of the PDE to HITS medium with 8-CI cAMP conferred
growth inhibition on MCF-7 cells (section 3.20), and a number of
metabolite peaks were detected by HPLC of the medium (section
3.26). These data indicate that the crude heart PDE preparation
probably contained other metabolising enzymes, since the 8-CI
adenosine metabolite disappeared, and other metabolite peaks
increased in size after incubation with 8-CI cAMP. In contrast,
the fact that no other metabolite peak, other than 8-CI adenosine,
could be detected after incubation in medium containing FCS
suggest that only phosphodiesterase and 5'-nucleotidase are
present, and adenosine deaminase is not. The HPLC data also
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suggest that the rate-limiting step in the conversion of 8-CI
cAMP to 8-CI adenosine is PDE and not nucleotidase, since no 8-CI
AMP could be detected. The concentration of 8-CI adenosine
detected by HPLC appeared to relate to the growth inhibitory
effects demonstrated on by thymidine incorporation with MCF-7
cells. In other words, the level of growth inhibition correlated
with the concentration of 8-CI adenosine in the medium (for
examples see sections 3.28.1; 3.11 & 3.21.3; 3.18 & 3.24). In
addition, the apparent differences in the growth inhibitory effect
of 8-CI cAMP (10 (iM) with different sera could be explained by
the relative levels of hydrolysis of 8-CI cAMP. Human serum
appeared to have a lower level of 8-CI cAMP hydrolysis than FCS
and mouse serum (section 3.28).
4.10 Toxicity of 8-Br Adenosine
Data described in section 3.23 show that 8-Br cAMP was
metabolised to the same extent as 8-CI cAMP, but 8-Br cAMP is
approximately ten times less potent at growth inhibition (section
3.14).
The bromine atom is larger than the chlorine with the result
that the molecule is stearically hindered to greater degree, and
cannot rotate around the N9-Ci bond between the purine and the
ribose moieties (see diagram 2). The result of this hindrance for
bromine is that the syn conformation predominates (Stolarski et
al., 1980). It is possible that the inhibitory properties of these
cAMP analogues require them to be in the anti conformation,
therefore making 8-CI adenosine more potent than 8-Br
adenosine. This idea of conformation implies that use of larger
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halogens than bromine would decrease the toxicity of the
adenosine analogue and a fluorine atom may improve toxicity
because of its smaller size compared to chlorine.
4.11 Serum-Free Culture Conditions
This thesis has indicated the importance of culturing
conditions for assessing the activity of drugs, especially drugs
that are developed with the intention of directly affecting a
biological system. It is, therefore, important to ensure that any
biological effect observed as the result of drug is not due to a
metabolite by the culture conditions. Many cell lines are being
developed that can proliferate in serum-free conditions and these
antiproliferative drugs should still have activity in these
systems. In the past, serum was added to culturing conditions
because it contained the essential ingredients required to
maintain cellular proliferation. The components of serum
essential for maintaining cultures are slowly being identified;
the process is slow since different cell lines require different
components and at different concentrations. Using serum-free
conditions the culturing environment becomes less complicated
providing a simpler system for the study of drug mechanism.
4.12 The Future of Site-Selective cAMP Analogues
A mass of data has been accumulated by Y.S. Cho-Chung's group
and colleagues that suggest that 8-CI cAMP affects the
proliferation of cancer cells, with little effect on "normal" cell
lines, and does so via a non-toxic mechanism (Reviewed by Cho-
Chung, 1990). Detailed studies of the mechanism of action has
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implicated the Rllp receptor, ras and myc oncogenes, and growth
factor production. The majority of these studies were carried out
in serum containing conditions. All these data appeared promising
for the clinical situation as a new treatment for cancer. However,
a recent preclinical pharmacology study with 8-CI cAMP in dogs
placed some doubt on the use of this analogue due to the severity
of drug-induced toxicity (Tomaszewski et al., 1991). Two
metabolites were detected in the plasma of several dogs, 8-
chloroxanthine and 8-chloro-2-hydroxyadenosine. The metabolism
of 8-CI cAMP in dogs parallel the data of Van Lookeren
Campagne's group and this thesis. The specific cancer-targeting
effect of these site-selective cAMP analogues appear to be lost
when they are metabolised to toxic metabolites. In light of this
data, the cancer lines previously reported to be sensitive to site-
selective cAMP analogues should be re-assessed using serum-free
medium to determine those lines, and potentially the type of
cancers, that are directly responsive to the analogue as opposed
to the toxic metabolite. In-vivo, it is more than likely that 8-CI
cAMP will be hydrolysed by patients' plasma resulting in
production of the toxic metabolite. This could result in the loss
of the expected cancer specificity by 8-CI cAMP, and make it no
better than other anti-cancer agents that function by
cytotoxicity. Alternatively, if cancer cell proliferation is more
susceptible to inhibition than normal cells, as suggested by the
majority of the literature, then development of other analogues
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